What i should buy with cipro

The initial buy antibiotics outbreak bactrim vs cipro prostatitis last year what i should buy with cipro sent labs and health systems across the country rushing to create tests for the novel cipro. Now, more than a year and a half into the cipro, people can get drive-through buy antibiotics testing at community sites and drugstores and even order antigen tests from Amazon to take at home. Over-the-counter rapid antigen tests for buy antibiotics have become very popular.But which tests should you what i should buy with cipro use and when?.

And if you are vaccinated, do you need to be testing at all?. Two UC Davis Health experts offer some updates and advice.Asymptomatic buy antibiotics testingAsymptomatic testing means getting tested when you don’t have any symptoms and don’t feel sick. Although it what i should buy with cipro might seem pointless to get tested when you are fine, asymptomatic testing has been a key strategy in tackling the cipro.

It can identify people who may have the buy antibiotics cipro — and are spreading it — but don’t know they’re infected.“When case rates are high, as they are right now, asymptomatic testing is an essential screening tool to identify cases and limit transmission,” said Sheri Belafsky, a UC Davis Health physician and the medical director for Healthy Yolo Together. The free testing program was originally offered to students what i should buy with cipro and staff at UC Davis and residents in the city of Davis. It has now expanded and conducts saliva-based buy antibiotics testing for all of Yolo County.

It is also supporting weekly saliva testing in schools throughout Yolo County as students return to in-person learning. Recent testing shows that cases are on the rise, which what i should buy with cipro worries health experts. €œHealthy Yolo Together is seeing our highest case positivity rates since we began community testing in mid-November 2020,” Belafsky said.

€œThis spike in cases associated with the Delta variant underscores the importance of asymptomatic testing to slow what i should buy with cipro further community spread.” And even if you are vaccinated, Belafsky still recommends asymptomatic testing. €œCurrently, one-quarter of our positive cases are in vaccinated individuals,” Belafsky said. For those who have access to testing, Belafsky recommends getting tested weekly.

Community testing sitesIf you’re experiencing buy antibiotics symptoms, you can make a same-day or after-hours telehealth appointment with UC Davis Express Care, which has what i should buy with cipro extended hours, including weekends and holidays. An Express Care doctor can help arrange a test for you. You can also contact your primary care provider.

UC Davis what i should buy with cipro Health patients can log in to MyUCDavisHealth. If you have a medical emergency, call 911 and describe your symptoms.buy antibiotics testing is widely availableEvidence of full vaccination or proof of a negative buy antibiotics test within 72 hours is now a requirement for visitors at many health care facilities. That includes California hospitals such what i should buy with cipro as UC Davis Medical Center, skilled nursing facilities, intermediate care facilities and adult and senior care residential facilities by order of the California Department of Public Health.

Fortunately, there are many places to get a buy antibiotics test.Sacramento, Placer, El Dorado, Yuba, Sutter, Yolo and other counties offer no-cost buy antibiotics testing at many locations. Some clinics are walk-in, and others require an appointment. Most testing is free, but some rapid tests require a what i should buy with cipro fee.The State of California also has a website with information about buy antibiotics testing and a searchable map listing different testing sites.

buy antibiotics testing is also widely available at drugstores such as CVS, Walgreens and Rite Aid.Where to get vaccinatedTo find locations with walk-up treatment clinics or to schedule an appointment, visit California’s My Turn website. Healthy Yolo Together’s free saliva-based testing is an easy way people what i should buy with cipro can test for the cipro that causes buy antibiotics. €œThere are now many places you can go to get free buy antibiotics testing,” said Nam Tran, senior director of clinical pathology in charge of buy antibiotics testing at UC Davis Health.

Counties across California offer free testing, including polymerase chain reaction or PCR testing, which is the gold standard in testing for the cipro. Many also offer the more rapid antigen test what i should buy with cipro. These tests are conducted at drive-through locations, walk-in clinics and even at pharmacies.

For people who what i should buy with cipro don’t want to take advantage of county and state testing, there are at-home options. Rapid Antigen Tests“The Food and Drug Administration has provided Emergency Use Authorization for hundreds of tests, including over-the-counter tests that can be used at home and without a prescription,” Tran said. €œFor about $20 to $30 on Amazon or at a drugstore, you can get an over-the-counter rapid antigen self-test kit.

These home kits usually come with two tests, and you can use an app to what i should buy with cipro track your results. The results take about 15 to 20 minutes.” The FDA has created a web page that lists the over-the-counter antigen tests that have been authorized through Emergency Use Authorization, or EUA. Tests include BinaxNOW buy antibiotics Ag Card, Ellume Lab buy antibiotics Antigen Test, Sofia SARS Antigen FIA, InteliSwab buy antibiotics Rapid Test Rx and many others.

These are sold online and at drugstores what i should buy with cipro. The rapid antigen tests search for protein pieces from the cipro. Although convenient, what i should buy with cipro they are less reliable than molecular PCR tests, which detect the cipro’s genetic material — RNA.

Rapid antigen tests are best used as intended, where a person tests at least twice over a 36- to 48-hour period to increase the odds of detecting an . PCR TestsFor those who want to do PCR tests at home, there are also over-the-counter kits. €œYou can purchase them online, take the test, what i should buy with cipro and then mail it in.

You get results back in about 48 hours. Amazon even has their own PCR test that provides results within 24 hours of their lab receiving it what i should buy with cipro – so realistically it is about 48 hours since you have to account for shipping time,” Tran said. PCR tests, like the ones used by UC Davis Health’s lab, are close to 100% accurate in diagnosing a buy antibiotics , but the disadvantage is they take more time for results.

The exception is the UC Davis rapid PCR test deployed last November, which provides results in 20 minutes. However, these tests are what i should buy with cipro restricted to high-risk emergency patients. Rapid antigen tests can provide results quickly, sometimes in as little as 15 minutes, but they are less accurate and give more false negatives compared to PCR tests.

Which test what i should buy with cipro to use?. €œPeople need to be mindful that not all tests are created the same, and with all home-use tests on the market, whether antigen or PCR, following testing instructions becomes very important to ensure the quality of testing,” Tran said. Healthy Yolo Together uses a saliva-based testing method to detect buy antibiotics.For example, if a swab isn’t inserted deeply enough into the nose, it may not collect a good sample for testing and may give a false negative.

Tran is often asked which type of test, antigen or PCR, is best, but he explained what i should buy with cipro that it depends on why someone is being tested. €œRapid antigen tests are now being used at schools for rapid screening. They are good for this purpose.

Or maybe your kid has been exposed at school, and what i should buy with cipro after quarantining per the CDC guidelines, they need to have two negatives tests. So, the parents may want to buy a rapid antigen home kit,” Tran said. But in other instances, a molecular PCR test, which is highly accurate, is what i should buy with cipro more appropriate.

"A PCR test can be used for asymptomatic testing or to confirm a positive antigen test, or when patients are experiencing symptoms, or need to be tested before a procedure, or when they are being admitted to the hospital. Our tests are for facilitating clinical decision-making,” Tran said. For Tran, what i should buy with cipro all buy antibiotics tests — whether antigen or PCR or saliva screening — are tools that provide important information.

€œTesting is merely a way to mitigate the cipro so everyone can get vaccinated. Testing was never what i should buy with cipro intended to be the only solution to get us out of the cipro,” Tran said. For more information about testing, appointments and treatments, visit the UC Davis Health antibiotics website.The Accelerated Access Unit of UC Davis Medical Center received the AMSN PRISM Award®, a national medical-surgical (med-surg) award recognizing the collective achievements and contributions of the nursing staff of the unit.

Nurse Manager Darrell Desmond, third from left, and Accelerated Access Unit members celebrate their PRISM Award.Med-surg nurses care for patients who are either preparing for or recovering from a surgery.The award, which stands for Premier Recognition in the Specialty of Med-Surg, is the first of its kind honoring med-surg nursing units in the United States and internationally. It is co-sponsored by the Academy of Medical-Surgical Nurses (AMSN) and the Medical-Surgical Nursing Certification what i should buy with cipro Board (MSNCB). The award is given to outstanding acute care/med-surg units or adult/pediatric units classified as med-surg.Officials representing the AMSN and MSNCB presented the Accelerated Access team with the award during a virtual ceremony Sept.

8. They applauded those gathered with exemplifying the qualities that define excellence in medical-surgical nursing and praised their journey to optimal outcomes and exceptional patient care.“I am more than proud of our PRISM designation,” said Darrell Desmond, nurse manager for the team known as Unit 4. €œFor us to maintain that level of expert holistic care over such a challenging time with buy antibiotics is amazing and should be celebrated.”Accelerated Access is a 34-bed adult med-surg unit.

Patients are a combination of short stays and admissions from the Emergency Department (ED) and clinics. Many patients come to the unit to await placement in a specialty unit such as Oncology. Because of its purpose and unit structure, patient turnover is very high, resulting in an extremely well-coordinated team of professional nurses.

€œYou and your team were the first hospital in California to receive a PRISM Award. You are still the number one hospital in California with six awards. And you are the only facility west of the Mississippi with six or more.

Y’all are rocking it!. €â€” Wes Foster PRISM Award presenterThe team achieved advanced scores in Leadership, Recruitment and Retention, and Lifelong Learning. They earned a near-perfect score for Patient Outcomes and a perfect score for the Healthy Practice Environment category.“I congratulate the entire team for their work — day in and day out — to create an environment that benefits both patients and staff,” added Toby Marsh, chief nursing and patient care services officer for UC Davis Medical Center.

€œI’m grateful for their commitment to staff recognition and community projects as well as daily huddles and behavioral health planning to improve patient care and illustrate how UC Davis Health is improving lives and transforming health care.”Wes Foster, president-elect of the MSNCB Board of Directors, jokingly mentioned Marsh’s competitive streak when presenting the award.“Toby, you and your team were the first hospital in California to receive a PRISM Award. You are still the number one hospital in California with six awards. And you are the only facility west of the Mississippi with six or more,” Foster said.

€œY’all are rocking it!. €More than 600,000 medical-surgical nurses practice in the U.S. Today, making them the single largest group of specialty nurses working in hospital settings, according to AMSN.

Med-surg nurses oversee a broad spectrum of patient care responsibilities, another reason the acronym PRISM was chosen for the award..

Can cipro be used for tooth

Cipro
Furacin
Duration of action
Order online
At cvs
Brand
Pharmacy
On the market
Dosage
Pharmacy
RX pharmacy
How long does stay in your system
750mg 32 tablet $59.95
0.2% 10g 6 cream $35.95

Tribulus terrestris is a botanical ingredient that is commonly used in Chinese and Indian medicine can cipro be used for tooth . When combined with other ingredients, tribulus promotes healthy testosterone levels while also increasing strength. Long Jack Eurycoma Root is another all-natural ingredient. Also known as tongkat ali, the roots of the plant have shown to increase muscle strength while also elevating serum testosterone can cipro be used for tooth levels.

Price Point A bottle of Elm &. Rye Testosterone Support costs $84.99. Each bottle contains 30 tablets, which equals out to about $2.83 can cipro be used for tooth per tablet. All U.S.

Orders ship for free. While not the cheapest testosterone booster on can cipro be used for tooth the market, when you buy from Elm &. Rye, you can have total confidence that you're spending your hard earned money on a quality supplement. To save money, sign up for the Subscribe &.

Save program can cipro be used for tooth . This saves you 20% on your order, which brings the total down to $67.99, or $2.26 per tablet. 2. Nitric Oxide Booster by Snap Supplements Give your muscles the fuel they need with can cipro be used for tooth Nitric Oxide Booster by Snap Supplements.

This product supports blood pressure and helps to regulate circulation. It's been shown to improve lung function and respiratory health, while also promoting a healthy immune system. While not marketed as a muscle gainer, Nitric Oxide Booster does just that can cipro be used for tooth . The supplement has been endorsed by some of the biggest names in the weightlifting industry, including Petros Arzoumanidis.

By increasing circulation, Nitric Oxide Booster works to optimally feed your muscles during workouts. This means that with each rep, your body's can cipro be used for tooth output will increase!. Nitric Oxide Booster also improves recovery. You'll notice that your muscles feel less fatigued and that you're more than ready to tackle the next day's workout.

What’s can cipro be used for tooth In It?. Nitric Oxide Booster is made with a blend of all natural botanical and herbal ingredients, including. L-Arginine Together, these ingredients work to support blood circulation while also boosting the respiratory system. Muira Puama has been used for hundreds of years as a natural energy can cipro be used for tooth tonic.

It is known for boosting drive and stamina. Asian ginseng root is well-studied and has been linked to all sorts of benefits, including normalized blood pressure levels and a healthier circulatory system. L-Citrulline can cipro be used for tooth and L-Arginine, two essential amino acids, are nitric oxide precursors. They work by dilating the blood vessels, which allows for a higher amount of oxygen and nutrients to be delivered to the organs and muscles.

Price Point Nitric Oxide Booster is easy on the wallet. Each bottle, which contains can cipro be used for tooth 60 capsules (30 servings), costs just $27.95. At less than $1 per serving, this supplement is a steal. You can save even more with the Subscribe and save program, which brings the monthly cost down to $23.95, or $0.79 per serving.

3. 5% Nutrition Bigger by The Day There are endless muscle building supplements on the market, but 5% Nutrition has worked to develop a potent, legal product that offers all of the benefits you need when trying to build muscle. 5% Nutrition Bigger by The Day works by promoting protein synthesis, stimulating nitric oxide production, and decreasing recovery time. 5% Nutrition Bigger by The Day is made with a potent absorption enhancer, which icnreases bioavailability while offering maximum absorption.

If you love a good intense hardcore workout, this is the supplement for you. What’s In It?. Bigger by the Day contains a unique blend of ingredients, including vitamins, minerals, herbs, and botanicals. Each capsule offers.

Vitamin A Black Pepper Extract Alpha Hydroxyisocaproic Acid is an anti-catabolic substance, which means it protects the muscle while also increasing muscle protein synthesis. 5a-Hydroxy Laxogenin is a plant-based anabolic compound that accelerates lean muscle mass growth, breaks down fat cells, and increases protein synthesis. Other ingredients like Green Tea Extract improves muscle recovery after strenuous exercise. It also minimizes oxidative stress and muscle damage in athletes.

Together, these ingredients work to boost energy levels, support lean muscle development, and speed up recovery so that you can get back in the gym feeling your best. Price Point 5% Nutrition Bigger by The Day is available from several online supplement stores for $64.99. Each bottle contains 90 capsules, which is enough to last at least a month, assuming the maximum dose of three pills a day. Though not the cheapest supplement, it's also not the most expensive either.

A serving will cost you $2.16, which is a fair deal, considering the quality ingredients that are provided in each capsule. 4. Magnum Nutraceuticals Hard Muscle Builder Looking for a strong muscle builder that will make you feel stronger?. Want to put on mass faster than ever before?.

If so, check out this muscle building supplement. Magnum Nutraceuticals Hard Muscle Builder is designed to increase energy levels while also enabling quicker recovery. It's formulated with three patented ingredients that maximize muscle gains, which means that none of your hard work will go to waste. Magnum Nutraceuticals Hard Muscle Builder boosts testosterone levels while lowering stress and anxiety.

If you're looking for a muscle building supplement that's backed by years of science and research, this is the one for you. Get the physique you've been working for!. What’s In It?. Unlike other muscle building supplements, Hard Muscle Builder has a short and simple ingredients list.

Each capsule provides a blend of. Vitamin D3 myHMB® (Calcium beta-Hydroxy-beta-Methylbutyrate Monohydrate) KSM-66® (Ashwaghanda Root Extract 5% Withanolides) PureKIC® (Alpha-Ketoisocaproate Calcium) myHMB® works to prevent protein breakdown and muscle wasting. It also improves exercise performance so that you can pack on the muscle. Studies have found that HMB has a nitrogen sparing effect, which means that it slows blood lactate accumulation.

The result?. More time to reach VO2 max. KSM-66® is the industry's adaptogen form of the Ayurvedic herb ashwaganda. It greatly improves muscle strength and size due to its natural ability to increase testosterone levels.

The ingredient also reduces exercise-induced muscle damage. With PureKIC®, you can knock out more reps without worrying about muscle damage. This compound is a keto acid. It's anti-catabolic and has shown to improve nitrogen balance while increasing protein synthesis.

It even promotes fat loss while protecting the body from oxidative stress. Price Point Hard Muscle Builder is available for $44.99 per bottle. Each bottle provides 90 capsules, which equates to a month's serving. Each serving costs less than $1.50, making it super affordable.

When purchased from certain retailers, you'll be covered with a money back guarantee. If you're unhappy with the product, you can return it for a full refund. 5. Redcon1 Moab Final Thoughts Building muscle takes a lot of hard work and dedication.

Not only do you have to spend hours at the gym, you have to eat a high-protein diet that promotes muscle gain. By taking a muscle builder supplement, you’ll find that it’s a little easier to build lean mass. We highly recommend the five supplements on our list. Elm &.

Rye Testosterone Support is the best product for men who are looking to get stronger while also getting leaner. However, any of these supplements will help you achieve the results you’re looking for.This article contains affiliate links to products. We may receive a commission for purchases made through these links.When it comes to good sleep, most of us don’t get enough. It’s estimated that at least half of all Americans either don’t get sufficient sleep or aren’t getting high-quality sleep.

Sleeping pills, of course, are an option, but some can leave you at risk of becoming dependent on them. Instead of reaching for sleeping pills, try a more natural approach with natural magnesium.Each brand on this list offers high-quality magnesium in a singular blend or proprietary blend of vitamins, minerals, and extracts. Every ingredient is sourced naturally for only the best experience. Magnesium HelpsMagnesium is one of the most important minerals in the body.

It helps calm aching muscles and can even be used to help address other conditions. This makes it the best option for anyone looking to improve the quality of their sleep without becoming dependent on sedatives. Most of us don’t get our recommended dose of magnesium, so you’re also getting the added benefit of increasing your daily intake of this crucial mineral. The Best Magnesium Supplements for SleepNot all supplements are created equal, so it’s time to jump into our list so you can make a better purchasing decision the next time you buy.

1. Elm &. RyeBenefits For Sleep. Elm &.

Rye’s potent, high-quality magnesium supplement is first on our list for a simple reason. It’s the best you can get. From the ingredients to the price and the service Elm &. Rye offers, you’re getting a one-of-a-kind experience.

Elm &. Rye’s magnesium supplement will help your mind relax, providing you with a potent dose of 700mg to calm the body and mind.Quality Of Ingredients. You won’t find better ingredients with other brands. Every supplement from Elm &.

Rye contains only the highest-quality, 100% natural ingredients sourced sustainably whenever possible. Cost Comparison. Not only are you getting incredible savings from Elm &. Rye’s affordable pricing, but you’re also getting maximum value from the high-quality ingredients.

A 30-day supply of Elm &. Rye’s magnesium costs $50, which makes it the best value on this list. You just can’t get better ingredients or customer service, or a commitment to quality that’s actually maintained. Overall Rating.

Overall, Elm &. Rye’s magnesium earns a 5/5 rating for its consistency, quality, and excellent value. 2. Natural Vitality CALM Anti-Stress MixBenefits For Sleep.

When it comes to sleep, stress is what keeps most of us tossing and turning throughout the night. In fact, more than half of all Americans don’t get enough sleep, and stress is the leading cause of anxiety-related problems. The solution?. A delicious anti-stress drink mix that’s loaded with high-quality, potent magnesium for a sleep you won’t forget.Quality Of Ingredients.

Natural Vitality takes its ingredients seriously, and you’re getting 325 mg, or 77% of your daily value of magnesium (as magnesium carbonate). It’s easily absorbed and dissolves easily in water and other drinks. Pour it in your bedtime glass of water, and you’ll find peaceful, easy sleep. Cost Comparison.

Compared to other brands, this product is about average when it comes to price. A container of 16 oz. Of powder will cost you about $25, depending on where you buy from.Overall Rating. You can find the CALM anti-stress drink mix available on most supplement websites and on Amazon.

You can find it at CVS as well. 3. Life Extension Magnesium CapsBenefits For Sleep. These potent magnesium caps from Life Extension contain only the best magnesium as magnesium oxide, succinate, and glycinate chelate.

The easily absorbed vegetarian capsules provide a calming effect, supporting bone, heart, and neurological health as well. If you’re looking for clean, sustainable, affordable magnesium, this is it. Each capsule contains 500mg of magnesium, making it one of the more potent supplements out there.Quality Of Ingredients. Life Extension takes its ingredients seriously, which is why the capsules are vegetarian-friendly and certified GMO-free.

You’ll also get the added benefit of Life Extension’s 100% money-back satisfaction guarantee. If you’re not happy, return the supplement for a full refund.Cost Comparison. Compared to other brands, Life Extension Magnesium Caps come in on the lower end of the price spectrum, at just $9 per bottle. Each bottle contains a 100-day supply.

Overall Rating. Overall, we give Life Extension a 4.6/5 rating for its GMO-free, high-quality ingredients, low price, and money-back guarantee. 4. SunDown MagnesiumBenefits For Sleep.

SunDown Magnesium is a product you’ll want to consider the next time you’re having trouble sleeping. Each caplet contains a potent dose of 500mg of magnesium oxide, which absorbs quickly and gets to work right away. Not to mention, the brand is free of GMOs and other artificial ingredients, so nothing is getting in the way of your sleep.Quality Of Ingredients. SunDown Magnesium caplets contain no GMOs, preservatives, artificial flavors, or sub-par ingredients.

The brand takes a pledge of providing only the best quality natural ingredients for its supplements, and it shows when you start taking them.Cost Comparison. As far as cost goes, SunDown Magnesium is one of the cheapest options on this list, with a 180-day supply coming in at just under $7 per bottle. You can also find the product on Amazon, where Prime’s free shipping option further increases the product’s value.Overall Rating. We give SunDown Magnesium a 4.3/5 for its commitment to GMO-free products and the low price of just under $7 per bottle.

5. Nature’s BountyBenefits For Sleep. Nature’s Bounty is one of the most trusted (and purchased) supplement brands in the country. You’ve probably seen the brand’s products on the shelves at the local drug store, retail store, or grocery store (the little green bottles).

Nature’s Bounty magnesium is just that — magnesium. There are no additives, so your magnesium starts working right away to help you get to sleep.Quality Of Ingredients. Nature’s Bounty may be on the cheaper end of the price spectrum, but the brand sacrifices nothing when it comes to quality. Each tablet contains 500 mg of magnesium as magnesium oxide, so it dissolves quickly and is absorbed right away.

Cost Comparison. Nature’s Bounty is one of the most affordable supplement brands on the market, and their magnesium tablets come in at just under $6 per bottle. Each bottle contains a 100-day supply. You can order Nature’s Bounty online, but your local grocery store, CVS, or Walgreens likely has the brand stocked already.

Overall Rating. We give Nature’s Bounty Magnesium a 4.6/5 for its quality, low price, and availability. 6. Nested Naturals Magnesium Glycinate ChelateBenefits For Sleep.

Magnesium glycinate chelate is easily-absorbed for a potent dose of magnesium, and Nested Naturals brings you a supplement that supports healthy bones, sleep habits, and more. Take these capsules before bed or once per day with a meal, and you’ll notice you sleep better and feel more well-rested when you wake up. Quality Of Ingredients. Nested Naturals offers high-quality, GMO-free ingredients.

These supplements are vegan-friendly, gluten, wheat, dairy, and preservative-free, and pack a punch with 200 mg of magnesium. That’s about 48% of your daily value of magnesium.Cost Comparison. When compared with other brands, Nested Naturals is one of the more affordable options available. A bottle of 120 capsules, or a 60-day supply, costs about $15 on Amazon with free shipping.Overall Rating.

We give Nested Naturals Magnesium Glycinate Chelate a 4.7/5. As one of the most affordable, high-quality, and versatile magnesium supplements, we recommend it for anyone struggling with their sleep habits.7. Essential Elements Magnesium Plus ZincBenefits For Sleep. When you need to get to sleep quickly, you need the best quality from your supplements.

You also need extra vitamins and minerals to ensure your magnesium is doing its job properly. That’s where Essential Elements comes in. The brand’s magnesium plus zinc tablet offers a potent dose of 225 mg of magnesium, plus zinc and vitamin D3.Quality Of Ingredients. Essential Elements is a brand you can trust when it comes to ingredients.

These magnesium tablets are gluten, shellfish, dairy, and sugar-free, and contain only the best natural sources of each vitamin and mineral. You’ll notice a difference right away. Cost Comparison. When compared with other similar brands, Essential Elements comes in at about average for magnesium supplements.

Each bottle contains 180 capsules at 225 mg (of magnesium) each, which is a 60-day supply at two servings per day. The cost is $15.95 on Amazon, with free shipping for Prime members.Overall Rating. Overall, Essential Elements Magnesium Plus Zinc earns a 4.6/5 rating for quality ingredients and an affordable price. Free shipping is a nice benefit, too.8.

Vital Nutrients Magnesium Glycinate/MalateBenefits For Sleep. Vital Nutrients brings you a highly-absorbable and potent form of magnesium to help you fall asleep quicker and stay asleep. The more rested you feel, the better your days will go, and the less responsive you’ll be to stressors. Vital Nutrients takes your health seriously, and this supplement is perfect for people of all ages looking to improve the quality of their sleep without addictive sleeping pills.Quality Of Ingredients.

Inside each capsule is 240 mg, or 60% of your daily value, of magnesium. Formatted as magnesium glycinate and malate (50% of each). This is absorbed quickly and works with the body naturally to calm your mind and body.Cost Comparison. Compared to other brands, this is an affordable option.

Each bottle costs about $21, and some supplement websites even offer free shipping. Overall Rating. Overall, we give Vital Nutrients Magnesium Glycinate/Malate a 4.1/5 rating for its quality ingredients, low cost, and effective blend of magnesium glycinate and malate. 9.

Onnit New Mood Daily Stress SupportBenefits For Sleep. Good sleep means getting to the source of your sleep disruption, and, for most of us, that’s stress. We experience stress constantly, and while not all stress is bad, most of it pulls at us all day and causes things like anxiety and restlessness. Onnit brings you this potent “New Mood” daily stress support supplement, complete with key vitamins and minerals, including magnesium.

Quality Of Ingredients. Inside each capsule, you’ll get niacin, magnesium, vitamin B6, the proprietary Onnit Tranquility Blend, and L-tryptophan. Each ingredient is naturally sourced and of the highest quality. Cost Comparison.

When compared to other brands, Onnit New Mood Daily Stress Support comes in at $30 per bottle, which is about average. Remember that you’re getting more than just magnesium with the stress support blend, effectively increasing its value. You can find it online at vitamin and supplement shops. Overall Rating.

10. NOW Foods True Calm Magnesium SupplementBenefits For Sleep. This True Calm magnesium supplement from NOW Foods is a potent blend of important vitamins and minerals formulated to bring about a sense of calm for deeper, more restful sleep and less stressful days. The supplement is designed to help the mind and body calm down, especially after a stressful day at work.

Quality Of Ingredients. NOW Foods True Calm contains magnesium, niacin, GABA (gamma-aminobutyric acid), Glycine, Taurine, Inositol, and Valerian root. This proprietary blend contains everything you need to relax, and each capsule gives you 13 mg of magnesium. NOW Foods’ ingredients are always sourced naturally, and you won’t find any harmful fillers or additives with this product.

It’s a great option for anyone who needs a boost that includes magnesium. Cost Comparison. Compared to other brands, NOW Foods True Calm Magnesium Supplement falls on the lower end of the pricing spectrum, at about $11 per bottle. Each bottle contains 90 veggie capsules, or a 90-day supply.

Overall Rating. We give this supplement a 4.7/5 rating for its affordability, potent proprietary blend of extracts and minerals, and availability. You can get it at GNC. 11.

Klean Athlete Klean MagnesiumBenefits For Sleep. Klean Athlete Klean Magnesium is made by athletes for athletes, with relaxation in mind. The blend helps calm muscles, which is something that can keep you from getting a good night’s sleep. We’ve all had muscle spasms and pain at night, which keeps us tossing and turning and reaching for painkillers, which cause drowsiness.

This is a more natural approach to muscle soreness and pain, and from a brand that’s well-known for its quality supplements.Quality Of Ingredients. Klean Athlete magnesium contains only magnesium glycinate, with no added fillers or ingredients. Magnesium is sourced naturally to ensure quality and potency. These vegetarian capsules are perfect for those with food sensitivities or preferences that don’t include animal products.Cost Comparison.

When compared with other brands, Klean Athlete Klean Magnesium comes in at the average end of the pricing spectrum, at about $21 per bottle. Each bottle contains 90 capsules, and the recommended dose is 1-4 per day (depending on a coach or doctor recommendation).Overall Rating. Overall, we give Klean Athlete a 4.8/5. Klean Athlete is one of the best brands out there, with awesome ingredients, low prices, and a quality guarantee you simply can’t ignore.

12. Klaire Labs Magnesium Glycinate ComplexBenefits For Sleep. Klaire Labs Magnesium Glycinate Complex is easy to absorb and acts quickly, helping your mind and body reach a state of calm so you can get to sleep quicker and stay asleep. It’s perfect for brain and heart health, also.

High-quality magnesium is what makes the difference in this brand, and Klaire Labs has been researching the best ingredients for decades.Quality Of Ingredients. Klaire Labs takes a scientific approach to its supplements, using science-backed, natural ingredients for a difference that you can feel with every dose. The supplement company is well-known in the world of personal health and aims to make a difference in the lives of all of its customers.Cost Comparison. When compared to other brands, Klaire Labs falls in at the bottom of the price spectrum, with a bottle of 100 capsules coming in at just $16.

Of course, the price also largely depends on where you’re buying from, but generally, this supplement stays below $20/bottle.Overall Rating. We give Klaire Labs Magnesium Glycinate Complex a 4.4/5 rating for its science-backed approach, good service, and low prices.13. Solgar Chelated MagnesiumBenefits For Sleep. Solgar is a name we all trust.

Price Point get redirected here A bottle of Elm & what i should buy with cipro. Rye Testosterone Support costs $84.99. Each bottle contains 30 tablets, which equals out to about $2.83 per tablet. All U.S what i should buy with cipro.

Orders ship for free. While not the cheapest testosterone booster on the market, when you buy from Elm &. Rye, you can have total what i should buy with cipro confidence that you're spending your hard earned money on a quality supplement. To save money, sign up for the Subscribe &.

Save program. This saves you 20% on your order, which what i should buy with cipro brings the total down to $67.99, or $2.26 per tablet. 2. Nitric Oxide Booster by Snap Supplements Give your muscles the fuel they need with Nitric Oxide Booster by Snap Supplements.

This product supports blood pressure what i should buy with cipro and helps to regulate circulation. It's been shown to improve lung function and respiratory health, while also promoting a healthy immune system. While not marketed as a muscle gainer, Nitric Oxide Booster does just that. The supplement has been endorsed by some what i should buy with cipro of the biggest names in the weightlifting industry, including Petros Arzoumanidis.

By increasing circulation, Nitric Oxide Booster works to optimally feed your muscles during workouts. This means that with each rep, your body's output will increase!. Nitric Oxide Booster also improves what i should buy with cipro recovery. You'll notice that your muscles feel less fatigued and that you're more than ready to tackle the next day's workout.

What’s In It?. Nitric Oxide Booster is made with a blend of all what i should buy with cipro natural botanical and herbal ingredients, including. L-Arginine Together, these ingredients work to support blood circulation while also boosting the respiratory system. Muira Puama has been used for hundreds of years as a natural energy tonic.

It is known for boosting drive and what i should buy with cipro stamina. Asian ginseng root is well-studied and has been linked to all sorts of benefits, including normalized blood pressure levels and a healthier circulatory system. L-Citrulline and L-Arginine, two essential amino acids, are nitric oxide precursors. They work by what i should buy with cipro dilating the blood vessels, which allows for a higher amount of oxygen and nutrients to be delivered to the organs and muscles.

Price Point Nitric Oxide Booster is easy on the wallet. Each bottle, which contains 60 capsules (30 servings), costs just $27.95. At less than $1 per serving, this supplement what i should buy with cipro is a steal. You can save even more with the Subscribe and save program, which brings the monthly cost down to $23.95, or $0.79 per serving.

3. 5% Nutrition Bigger by The Day There are endless muscle building supplements on the market, what i should buy with cipro but 5% Nutrition has worked to develop a potent, legal product that offers all of the benefits you need when trying to build muscle. 5% Nutrition Bigger by The Day works by promoting protein synthesis, stimulating nitric oxide production, and decreasing recovery time. 5% Nutrition Bigger by The Day is made with a potent absorption enhancer, which icnreases bioavailability while offering maximum absorption.

If you love a good intense hardcore workout, this is the supplement for what i should buy with cipro you. What’s In It?. Bigger by the Day contains a unique blend of ingredients, including vitamins, minerals, herbs, and botanicals. Each capsule offers what i should buy with cipro.

Vitamin A Black Pepper Extract Alpha Hydroxyisocaproic Acid is an anti-catabolic substance, which means it protects the muscle while also increasing muscle protein synthesis. 5a-Hydroxy Laxogenin is a plant-based anabolic compound that accelerates lean muscle mass growth, breaks down fat cells, and increases protein synthesis. Other what i should buy with cipro ingredients like Green Tea Extract improves muscle recovery after strenuous exercise. It also minimizes oxidative stress and muscle damage in athletes.

Together, these ingredients work to boost energy levels, support lean muscle development, and speed up recovery so that you can get back in the gym feeling your best. Price Point 5% Nutrition Bigger by The Day is what i should buy with cipro available from several online supplement stores for $64.99. Each bottle contains 90 capsules, which is enough to last at least a month, assuming the maximum dose of three pills a day. Though not the cheapest supplement, it's also not the most expensive either.

A serving will cost you $2.16, which is a fair deal, considering the quality ingredients that are provided in each capsule what i should buy with cipro. 4. Magnum Nutraceuticals Hard Muscle Builder Looking for a strong muscle builder that will make you feel stronger?. Want to put on what i should buy with cipro mass faster than ever before?.

If so, check out this muscle building supplement. Magnum Nutraceuticals Hard Muscle Builder is designed to increase energy levels while also enabling quicker recovery. It's formulated with three patented ingredients that maximize muscle gains, which means that none of your hard work will what i should buy with cipro go to waste. Magnum Nutraceuticals Hard Muscle Builder boosts testosterone levels while lowering stress and anxiety.

If you're looking for a muscle building supplement that's backed by years of science and research, this is the one for you. Get the physique what i should buy with cipro you've been working for!. What’s In It?. Unlike other muscle building supplements, Hard Muscle Builder has a short and simple ingredients list.

Each capsule provides a blend what i should buy with cipro of. Vitamin D3 myHMB® (Calcium beta-Hydroxy-beta-Methylbutyrate Monohydrate) KSM-66® (Ashwaghanda Root Extract 5% Withanolides) PureKIC® (Alpha-Ketoisocaproate Calcium) myHMB® works to prevent protein breakdown and muscle wasting. It also improves exercise performance so that you can pack on the muscle. Studies have found that HMB has what i should buy with cipro a nitrogen sparing effect, which means that it slows blood lactate accumulation.

The result?. More time to reach VO2 max. KSM-66® is the industry's adaptogen form of the Ayurvedic herb ashwaganda what i should buy with cipro. It greatly improves muscle strength and size due to its natural ability to increase testosterone levels.

The ingredient also reduces exercise-induced muscle damage. With PureKIC®, you can knock out more reps without worrying about what i should buy with cipro muscle damage. This compound is a keto acid. It's anti-catabolic and has shown to improve nitrogen balance while increasing protein synthesis.

It even promotes fat what i should buy with cipro loss while protecting the body from oxidative stress. Price Point Hard Muscle Builder is available for $44.99 per bottle. Each bottle provides 90 capsules, which equates to a month's serving. Each serving costs less what i should buy with cipro than $1.50, making it super affordable.

When purchased from certain retailers, you'll be covered with a money back guarantee. If you're unhappy with the product, you can return it for a full refund. 5. Redcon1 Moab Final Thoughts Building muscle takes a lot of hard work and dedication.

Not only do you have to spend hours at the gym, you have to eat a high-protein diet that promotes muscle gain. By taking a muscle builder supplement, you’ll find that it’s a little easier to build lean mass. We highly recommend the five supplements on our list. Elm &.

Rye Testosterone Support is the best product for men who are looking to get stronger while also getting leaner. However, any of these supplements will help you achieve the results you’re looking for.This article contains affiliate links to products. We may receive a commission for purchases made through these links.When it comes to good sleep, most of us don’t get enough. It’s estimated that at least half of all Americans either don’t get sufficient sleep or aren’t getting high-quality sleep.

Sleeping pills, of course, are an option, but some can leave you at risk of becoming dependent on them. Instead of reaching for sleeping pills, try a more natural approach with natural magnesium.Each brand on this list offers high-quality magnesium in a singular blend or proprietary blend of vitamins, minerals, and extracts. Every ingredient is sourced naturally for only the best experience. Magnesium HelpsMagnesium is one of the most important minerals in the body.

It helps calm aching muscles and can even be used to help address other conditions. This makes it the best option for anyone looking to improve the quality of their sleep without becoming dependent on sedatives. Most of us don’t get our recommended dose of magnesium, so you’re also getting the added benefit of increasing your daily intake of this crucial mineral. The Best Magnesium Supplements for SleepNot all supplements are created equal, so it’s time to jump into our list so you can make a better purchasing decision the next time you buy.

1. Elm &. RyeBenefits For Sleep. Elm &.

Rye’s potent, high-quality magnesium supplement is first on our list for a simple reason. It’s the best you can get. From the ingredients to the price and the service Elm &. Rye offers, you’re getting a one-of-a-kind experience.

Elm &. Rye’s magnesium supplement will help your mind relax, providing you with a potent dose of 700mg to calm the body and mind.Quality Of Ingredients. You won’t find better ingredients with other brands. Every supplement from Elm &.

Rye contains only the highest-quality, 100% natural ingredients sourced sustainably whenever possible. Cost Comparison. Not only are you getting incredible savings from Elm &. Rye’s affordable pricing, but you’re also getting maximum value from the high-quality ingredients.

A 30-day supply of Elm &. Rye’s magnesium costs $50, which makes it the best value on this list. You just can’t get better ingredients or customer service, or a commitment to quality that’s actually maintained. Overall Rating.

Overall, Elm &. Rye’s magnesium earns a 5/5 rating for its consistency, quality, and excellent value. 2. Natural Vitality CALM Anti-Stress MixBenefits For Sleep.

When it comes to sleep, stress is what keeps most of us tossing and turning throughout the night. In fact, more than half of all Americans don’t get enough sleep, and stress is the leading cause of anxiety-related problems. The solution?. A delicious anti-stress drink mix that’s loaded with high-quality, potent magnesium for a sleep you won’t forget.Quality Of Ingredients.

Natural Vitality takes its ingredients seriously, and you’re getting 325 mg, or 77% of your daily value of magnesium (as magnesium carbonate). It’s easily absorbed and dissolves easily in water and other drinks. Pour it in your bedtime glass of water, and you’ll find peaceful, easy sleep. Cost Comparison.

Compared to other brands, this product is about average when it comes to price. A container of 16 oz. Of powder will cost you about $25, depending on where you buy from.Overall Rating. You can find the CALM anti-stress drink mix available on most supplement websites and on Amazon.

You can find it how much does cipro cost at CVS as well. 3. Life Extension Magnesium CapsBenefits For Sleep. These potent magnesium caps from Life Extension contain only the best magnesium as magnesium oxide, succinate, and glycinate chelate.

The easily absorbed vegetarian capsules provide a calming effect, supporting bone, heart, and neurological health as well. If you’re looking for clean, sustainable, affordable magnesium, this is it. Each capsule contains 500mg of magnesium, making it one of the more potent supplements out there.Quality Of Ingredients. Life Extension takes its ingredients seriously, which is why the capsules are vegetarian-friendly and certified GMO-free.

You’ll also get the added benefit of Life Extension’s 100% money-back satisfaction guarantee. If you’re not happy, return the supplement for a full refund.Cost Comparison. Compared to other brands, Life Extension Magnesium Caps come in on the lower end of the price spectrum, at just $9 per bottle. Each bottle contains a 100-day supply.

Overall Rating. Overall, we give Life Extension a 4.6/5 rating for its GMO-free, high-quality ingredients, low price, and money-back guarantee. 4. SunDown MagnesiumBenefits For Sleep.

SunDown Magnesium is a product you’ll want to consider the next time you’re having trouble sleeping. Each caplet contains a potent dose of 500mg of magnesium oxide, which absorbs quickly and gets to work right away. Not to mention, the brand is free of GMOs and other artificial ingredients, so nothing is getting in the way of your sleep.Quality Of Ingredients. SunDown Magnesium caplets contain no GMOs, preservatives, artificial flavors, or sub-par ingredients.

The brand takes a pledge of providing only the best quality natural ingredients for its supplements, and it shows when you start taking them.Cost Comparison. As far as cost goes, SunDown Magnesium is one of the cheapest options on this list, with a 180-day supply coming in at just under $7 per bottle. You can also find the product on Amazon, where Prime’s free shipping option further increases the product’s value.Overall Rating. We give SunDown Magnesium a 4.3/5 for its commitment to GMO-free products and the low price of just under $7 per bottle.

5. Nature’s BountyBenefits For Sleep. Nature’s Bounty is one of the most trusted (and purchased) supplement brands in the country. You’ve probably seen the brand’s products on the shelves at the local drug store, retail store, or grocery store (the little green bottles).

Nature’s Bounty magnesium is just that — magnesium. There are no additives, so your magnesium starts working right away to help you get to sleep.Quality Of Ingredients. Nature’s Bounty may be on the cheaper end of the price spectrum, but the brand sacrifices nothing when it comes to quality. Each tablet contains 500 mg of magnesium as magnesium oxide, so it dissolves quickly and is absorbed right away.

Cost Comparison. Nature’s Bounty is one of the most affordable supplement brands on the market, and their magnesium tablets come in at just under $6 per bottle. Each bottle contains a 100-day supply. You can order Nature’s Bounty online, but your local grocery store, CVS, or Walgreens likely has the brand stocked already.

Overall Rating. We give Nature’s Bounty Magnesium a 4.6/5 for its quality, low price, and availability. 6. Nested Naturals Magnesium Glycinate ChelateBenefits For Sleep.

Magnesium glycinate chelate is easily-absorbed for a potent dose of magnesium, and Nested Naturals brings you a supplement that supports healthy bones, sleep habits, and more. Take these capsules before bed or once per day with a meal, and you’ll notice you sleep better and feel more well-rested when you wake up. Quality Of Ingredients. Nested Naturals offers high-quality, GMO-free ingredients.

These supplements are vegan-friendly, gluten, wheat, dairy, and preservative-free, and pack a punch with 200 mg of magnesium. That’s about 48% of your daily value of magnesium.Cost Comparison. When compared with other brands, Nested Naturals is one of the more affordable options available. A bottle of 120 capsules, or a 60-day supply, costs about $15 on Amazon with free shipping.Overall Rating.

We give Nested Naturals Magnesium Glycinate Chelate a 4.7/5. As one of the most affordable, high-quality, and versatile magnesium supplements, we recommend it for anyone struggling with their sleep habits.7. Essential Elements Magnesium Plus ZincBenefits For Sleep. When you need to get to sleep quickly, you need the best quality from your supplements.

You also need extra vitamins and minerals to ensure your magnesium is doing its job properly. That’s where Essential Elements comes in. The brand’s magnesium plus zinc tablet offers a potent dose of 225 mg of magnesium, plus zinc and vitamin D3.Quality Of Ingredients. Essential Elements is a brand you can trust when it comes to ingredients.

These magnesium tablets are gluten, shellfish, dairy, and sugar-free, and contain only the best natural sources of each vitamin and mineral. You’ll notice a difference right away. Cost Comparison. When compared with other similar brands, Essential Elements comes in at about average for magnesium supplements.

Each bottle contains 180 capsules at 225 mg (of magnesium) each, which is a 60-day supply at two servings per day. The cost is $15.95 on Amazon, with free shipping for Prime members.Overall Rating. Overall, Essential Elements Magnesium Plus Zinc earns a 4.6/5 rating for quality ingredients and an affordable price. Free shipping is a nice benefit, too.8.

Vital Nutrients Magnesium Glycinate/MalateBenefits For Sleep. Vital Nutrients brings you a highly-absorbable and potent form of magnesium to help you fall asleep quicker and stay asleep. The more rested you feel, the better your days will go, and the less responsive you’ll be to stressors. Vital Nutrients takes your health seriously, and this supplement is perfect for people of all ages looking to improve the quality of their sleep without addictive sleeping pills.Quality Of Ingredients.

Inside each capsule is 240 mg, or 60% of your daily value, of magnesium. Formatted as magnesium glycinate and malate (50% of each). This is absorbed quickly and works with the body naturally to calm your mind and body.Cost Comparison. Compared to other brands, this is an affordable option.

Each bottle costs about $21, and some supplement websites even offer free shipping. Overall Rating. Overall, we give Vital Nutrients Magnesium Glycinate/Malate a 4.1/5 rating for its quality ingredients, low cost, and effective blend of magnesium glycinate and malate. 9.

Onnit New Mood Daily Stress SupportBenefits For Sleep. Good sleep means getting to the source of your sleep disruption, and, for most of us, that’s stress. We experience stress constantly, and while not all stress is bad, most of it pulls at us all day and causes things like anxiety and restlessness. Onnit brings you this potent “New Mood” daily stress support supplement, complete with key vitamins and minerals, including magnesium.

Quality Of Ingredients. Inside each capsule, you’ll get niacin, magnesium, vitamin B6, the proprietary Onnit Tranquility Blend, and L-tryptophan. Each ingredient is naturally sourced and of the highest quality. Cost Comparison.

When compared to other brands, Onnit New Mood Daily Stress Support comes in at $30 per bottle, which is about average. Remember that you’re getting more than just magnesium with the stress support blend, effectively increasing its value. You can find it online at vitamin and supplement shops. Overall Rating.

10. NOW Foods True Calm Magnesium SupplementBenefits For Sleep. This True Calm magnesium supplement from NOW Foods is a potent blend of important vitamins and minerals formulated to bring about a sense of calm for deeper, more restful sleep and less stressful days. The supplement is designed to help the mind and body calm down, especially after a stressful day at work.

Quality Of Ingredients. NOW Foods True Calm contains magnesium, niacin, GABA (gamma-aminobutyric acid), Glycine, Taurine, Inositol, and Valerian root. This proprietary blend contains everything you need to relax, and each capsule gives you 13 mg of magnesium. NOW Foods’ ingredients are always sourced naturally, and you won’t find any harmful fillers or additives with this product.

It’s a great option for anyone who needs a boost that includes magnesium. Cost Comparison. Compared to other brands, NOW Foods True Calm Magnesium Supplement falls on the lower end of the pricing spectrum, at about $11 per bottle. Each bottle contains 90 veggie capsules, or a 90-day supply.

Overall Rating. We give this supplement a 4.7/5 rating for its affordability, potent proprietary blend of extracts and minerals, and availability. You can get it at GNC. 11.

Klean Athlete Klean MagnesiumBenefits For Sleep. Klean Athlete Klean Magnesium is made by athletes for athletes, with relaxation in mind. The blend helps calm muscles, which is something that can keep you from getting a good night’s sleep. We’ve all had muscle spasms and pain at night, which keeps us tossing and turning and reaching for painkillers, which cause drowsiness.

This is a more natural approach to muscle soreness and pain, and from a brand that’s well-known for its quality supplements.Quality Of Ingredients. Klean Athlete magnesium contains only magnesium glycinate, with no added fillers or ingredients. Magnesium is sourced naturally to ensure quality and potency. These vegetarian capsules are perfect for those with food sensitivities or preferences that don’t include animal products.Cost Comparison.

When compared with other brands, Klean Athlete Klean Magnesium comes in at the average end of the pricing spectrum, at about $21 per bottle. Each bottle contains 90 capsules, and the recommended dose is 1-4 per day (depending on a coach or doctor recommendation).Overall Rating. Overall, we give Klean Athlete a 4.8/5. Klean Athlete is one of the best brands out there, with awesome ingredients, low prices, and a quality guarantee you simply can’t ignore.

12. Klaire Labs Magnesium Glycinate ComplexBenefits For Sleep. Klaire Labs Magnesium Glycinate Complex is easy to absorb and acts quickly, helping your mind and body reach a state of calm so you can get to sleep quicker and stay asleep. It’s perfect for brain and heart health, also.

High-quality magnesium is what makes the difference in this brand, and Klaire Labs has been researching the best ingredients for decades.Quality Of Ingredients. Klaire Labs takes a scientific approach to its supplements, using science-backed, natural ingredients for a difference that you can feel with every dose. The supplement company is well-known in the world of personal health and aims to make a difference in the lives of all of its customers.Cost Comparison. When compared to other brands, Klaire Labs falls in at the bottom of the price spectrum, with a bottle of 100 capsules coming in at just $16.

Of course, the price also largely depends on where you’re buying from, but generally, this supplement stays below $20/bottle.Overall Rating. We give Klaire Labs Magnesium Glycinate Complex a 4.4/5 rating for its science-backed approach, good service, and low prices.13. Solgar Chelated MagnesiumBenefits For Sleep. Solgar is a name we all trust.

You probably recognize the dark amber bottles with the gold labeling, and Solgar has been respected all over the world for decades. These chelated magnesium tablets are sourced naturally, and contain magnesium in the forms of magnesium oxide, glycinate, and chelate. This potent mix helps calm the mind and is easily absorbed into the body for a quick reaction.Quality Of Ingredients. Solgar takes pride in the quality of its all-natural ingredients, ensuring that each tablet is free of artificial flavors, preservatives, wheat, dairy, soy, and gluten.

What is Cipro?

CIPROFLOXACIN is a quinolone antibiotic. It can kill bacteria or stop their growth. It is used to treat many kinds of s, like urinary, respiratory, skin, gastrointestinal, and bone s. It will not work for colds, flu, or other viral s.

Cipres altura

How to https://hbmoore.com/blog/ cite cipres altura this article:Singh OP. Psychiatry research in India. Closing the cipres altura research gap. Indian J Psychiatry 2020;62:615-6Research is an important aspect of the growth and development of medical science. Research in India in general and medical research in particular is always being cipres altura criticized for lack of innovation and originality required for the delivery of health services suitable to Indian conditions.

Even the Indian Council of Medical Research (ICMR) which is a centrally funded frontier organization for conducting medical research couldn't avert criticism. It has been criticized heavily for not producing quality research papers which are pioneering, ground breaking, or pragmatic solutions for health issues plaguing India. In the words of a leading daily, The ICMR could not even list one practical application of its hundreds of research papers published in various national and international research journals which helped cure any disease, or diagnose it with better accuracy or in less time, or even one new basic, applied or clinical research or cipres altura innovation that opened a new frontier of scientific knowledge.[1]This clearly indicates that the health research output of ICMR is not up to the mark and is not commensurate with the magnitude of the disease burden in India. According to the 12th Plan Report, the country contributes to a fifth of the world's share of diseases. The research conducted cipres altura elsewhere may not be generalized to the Indian population owing to differences in biology, health-care systems, health practices, culture, and socioeconomic standards.

Questions which are pertinent and specific to the Indian context may not be answered and will remain understudied. One of the vital elements in improving this situation is the need for relevant research base that would equip policymakers to take informed health policy decisions.The Parliamentary Standing Committee on Health and Family Welfare in the 100th report on Demand for Grants (2017–2018) of the Department of Health Research observed that “the biomedical research output needs to be augmented substantially to cater to the health challenges faced by the country.”[1]Among the various reasons, lack of fund, infrastructure, and resources is the prime cause which is glaringly evident from the inadequate budget allocation for biomedical research. While ICMR has a budget of 232 million dollars per year on health research, it is zilch in comparison to the annual budget expenditure of the National Institute of cipres altura Health, USA, on biomedical research which is 32 billion dollars.The lacuna of quality research is not merely due to lack of funds. There are other important issues which need to be considered and sorted out to end the status quo. Some of the factors which need our immediate attention are:Lack of research training and teachingImproper allocation of research facilitiesLack of information about research work happening globallyLack of promotion, motivation, commitment, and passion in the field of researchClinicians being overburdened with patientsLack of collaboration between medical colleges and established research institutesLack of continuity of research in successive batches of postgraduate (PG) students, leading to wastage of previous research and resourcesDifficulty in the application of basic biomedical research into pragmatic intervention solutions due to lack of interdisciplinary technological support/collaboration between basic scientists, clinicians, and technological cipres altura experts.Majority of the biomedical research in India are conducted in medical institutions.

The majority of these are done as thesis submission for fulfillment of the requirement of PG degree. From 2015 onward, publication of papers had been made an obligatory requirement for promotion of faculty to cipres altura higher posts. Although it offered a unique opportunity for training of residents and stimulus for research, it failed to translate into production of quality research work as thesis was limited by time and it had to be done with other clinical and academic duties.While the top four medical colleges, namely AIIMS, New Delhi. PGIMER, Chandigarh. CMC, Vellore cipres altura.

And SGIMS, Lucknow are among the top ten medical institutions in terms of publication in peer-reviewed journals, around 332 (57.3%) medical colleges have no research paper published in a decade between 2004 and 2014.[2]The research in psychiatry is realistically dominated by major research institutes which are doing commendable work, but there is a substantial lack of contemporary research originating from other centers. Dr. Chittaranjan Andrade (NIMHANS, Bengaluru) and Dr. K Jacob (CMC, Vellore) recently figured in the list of top 2% psychiatry researchers in the world from India in psychiatry.[3] Most of the research conducted in the field of psychiatry are limited to caregivers' burden, pathways of care, and other topics which can be done in limited resources available to psychiatry departments. While all these areas of work are important in providing proper care and treatment, there is overabundance of research in these areas.The Government of India is aggressively looking forward to enhancing the quality of research and is embarking on an ambitious project of purchasing all major journals and providing free access to universities across the country.

The India Genome Project started in January, 2020, is a good example of collaboration. While all these actions are laudable, a lot more needs to be done. Following are some measures which will reduce the gap:Research proposals at the level of protocol can be guided and mentored by institutes. Academic committees of different zones and journals can help in this endeavorBreaking the cubicles by establishing a collaboration between medical colleges and various institutes. While there is a lack of resources available in individual departments, there are universities and institutes with excellent infrastructure.

They are not aware of the requirements of the field of psychiatry and research questions. Creation of an alliance will enhance the quality of research work. Some of such institutes include Centre for Neuroscience, Indian Institute of Science, Bengaluru. CSIR-Institute of Genomics and Integrative Biology, New Delhi. And National Institute of Biomedical Genomics, KalyaniInitiation and establishment of interactive and stable relationships between basic scientists and clinical and technological experts will enhance the quality of research work and will lead to translation of basic biomedical research into real-time applications.

For example, work on artificial intelligence for mental health. Development of Apps by IITs. Genome India Project by the Government of India, genomic institutes, and social science and economic institutes working in the field of various aspects of mental healthUtilization of underutilized, well-equipped biotechnological labs of nonmedical colleges for furthering biomedical researchMedical colleges should collaborate with various universities which have labs providing testing facilities such as spectroscopy, fluoroscopy, gamma camera, scintigraphy, positron emission tomography, single photon emission computed tomography, and photoacoustic imagingCreating an interactive, interdepartmental, intradepartmental, and interinstitutional partnershipBy developing a healthy and ethical partnership with industries for research and development of new drugs and interventions.Walking the talk – the psychiatric fraternity needs to be proactive and rather than lamenting about the lack of resource, we should rise to the occasion and come out with innovative and original research proposals. With the implementation of collaborative approach, we can not only enhance and improve the quality of our research but to an extent also mitigate the effects of resource crunch and come up as a leader in the field of biomedical research. References 1.2.Nagoba B, Davane M.

Current status of medical research in India. Where are we?. Walawalkar Int Med J 2017;4:66-71. 3.Ioannidis JP, Boyack KW, Baas J. Updated science-wide author databases of standardized citation indicators.

PLoS Biol 2020;18:e3000918. Correspondence Address:Dr. Om Prakash SinghAA 304, Ashabari Apartments, O/31, Baishnabghata, Patuli Township, Kolkata - 700 094, West Bengal IndiaSource of Support. None, Conflict of Interest. NoneDOI.

10.4103/indianjpsychiatry.indianjpsychiatry_1362_2Abstract Background. The burden of mental illness among the scheduled tribe (ST) population in India is not known clearly.Aim. The aim was to identify and appraise mental health research studies on ST population in India and collate such data to inform future research.Materials and Methods. Studies published between January 1980 and December 2018 on STs by following exclusion and inclusion criteria were selected for analysis. PubMed, PsychINFO, Embase, Sociofile, Cinhal, and Google Scholar were systematically searched to identify relevant studies.

Quality of the included studies was assessed using an appraisal tool to assess the quality of cross-sectional studies and Critical Appraisal Checklist developed by Critical Appraisal Skills Programme. Studies were summarized and reported descriptively.Results. Thirty-two relevant studies were found and included in the review. Studies were categorized into the following three thematic areas. Alcohol and substance use disorders, common mental disorders and sociocultural aspects, and access to mental health-care services.

Sociocultural factors play a major role in understanding and determining mental disorders.Conclusion. This study is the first of its kind to review research on mental health among the STs. Mental health research conducted among STs in India is limited and is mostly of low-to-moderate quality. Determinants of poor mental health and interventions for addressing them need to be studied on an urgent basis.Keywords. India, mental health, scheduled tribesHow to cite this article:Devarapalli S V, Kallakuri S, Salam A, Maulik PK.

Mental health research on scheduled tribes in India. Indian J Psychiatry 2020;62:617-30 Introduction Mental health is a highly neglected area particularly in low and middle-income countries (LMIC). Data from community-based studies showed that about 10% of people suffer from common mental disorders (CMDs) such as depression, anxiety, and somatic complaints.[1] A systematic review of epidemiological studies between 1960 and 2009 in India reported that about 20% of the adult population in the community are affected by psychiatric disorders in the community, ranging from 9.5 to 103/1000 population, with differences in case definitions, and methods of data collection, accounting for most of the variation in estimates.[2]The scheduled tribes (ST) population is a marginalized community and live in relative social isolation with poorer health indices compared to similar nontribal populations.[3] There are an estimated 90 million STs or Adivasis in India.[4] They constitute 8.6% of the total Indian population. The distribution varies across the states and union territories of India, with the highest percentage in Lakshadweep (94.8%) followed by Mizoram (94.4%). In northeastern states, they constitute 65% or more of the total population.[5] The ST communities are identified as culturally or ethnographically unique by the Indian Constitution.

They are populations with poorer health indicators and fewer health-care facilities compared to non-ST rural populations, even when within the same state, and often live in demarcated geographical areas known as ST areas.[4]As per the National Family Health Survey, 2015–2016, the health indicators such as infant mortality rate (IMR) is 44.4, under five mortality rate (U5MR) is 57.2, and anemia in women is 59.8 for STs – one of the most disadvantaged socioeconomic groups in India, which are worse compared to other populations where IMR is 40.7, U5MR is 49.7, and anemia in women among others is 53.0 in the same areas.[6] Little research is available on the health of ST population. Tribal mental health is an ignored and neglected area in the field of health-care services. Further, little data are available about the burden of mental disorders among the tribal communities. Health research on tribal populations is poor, globally.[7] Irrespective of the data available, it is clear that they have worse health indicators and less access to health facilities.[8] Even less is known about the burden of mental disorders in ST population. It is also found that the traditional livelihood system of the STs came into conflict with the forces of modernization, resulting not only in the loss of customary rights over the livelihood resources but also in subordination and further, developing low self-esteem, causing great psychological stress.[4] This community has poor health infrastructure and even less mental health resources, and the situation is worse when compared to other communities living in similar areas.[9],[10]Only 15%–25% of those affected with mental disorders in LMICs receive any treatment for their mental illness,[11] resulting in a large “treatment gap.”[12] Treatment gaps are more in rural populations,[13] especially in ST communities in India, which have particularly poor infrastructure and resources for health-care delivery in general, and almost no capacity for providing mental health care.[14]The aim of this systematic review was to explore the extent and nature of mental health research on ST population in India and to identify gaps and inform future research.

Materials and Methods Search strategyWe searched major databases (PubMed, PsychINFO, Embase, Sociofile, Cinhal, and Google Scholar) and made hand searches from January 1980 to December 2018 to identify relevant literature. Hand search refers to searching through medical journals which are not indexed in the major electronic databases such as Embase, for instance, searching for Indian journals in IndMed database as most of these journals are not available in major databases. Physical search refers to searching the journals that were not available online or were not available online during the study years. We used relevant Medical Subject Heading and key terms in our search strategy, as follows. €œMental health,” “Mental disorders,” “Mental illness,” “Psychiatry,” “Scheduled Tribe” OR “Tribe” OR “Tribal Population” OR “Indigenous population,” “India,” “Psych*” (Psychiatric, psychological, psychosis).Inclusion criteriaStudies published between January 1980 and December 2018 were included.

Studies on mental disorders were included only when they focused on ST population. Both qualitative and quantitative studies on mental disorders of ST population only were included in the analysis.Exclusion criteriaStudies without any primary data and which are merely overviews and commentaries and those not focused on ST population were excluded from the analysis.Data management and analysisTwo researchers (SD and SK) initially screened the title and abstract of each record to identify relevant papers and subsequently screened full text of those relevant papers. Any disagreements between the researchers were resolved by discussion or by consulting with an adjudicator (PKM). From each study, data were extracted on objectives, study design, study population, study duration, interventions (if applicable), outcomes, and results. Quality of the included studies was assessed, independently by three researchers (SD, SK, and AS), using Critical Appraisal Checklist developed by Critical Appraisal Skills Programme (CASP).[15] After a thorough qualitative assessment, all quantitative data were generated and tabulated.

A narrative description of the studies is provided in [Table 1] using some broad categories. Results Search resultsOur search retrieved 2306 records (which included hand-searched articles), of which after removing duplicates, title and abstracts of 2278 records were screened. Of these, 178 studies were deemed as potentially relevant and were reviewed in detail. Finally, we excluded 146 irrelevant studies and 32 studies were included in the review [Figure 1].Quality of the included studiesSummary of quality assessment of the included studies is reported in [Table 2]. Overall, nine studies were of poor quality, twenty were of moderate quality, and three studies were of high quality.

The CASP shows that out of the 32 studies, the sample size of 21 studies was not representative, sample size of 7 studies was not justified, risk factors were not identified in 28 studies, methods used were not sufficiently described to repeat them in 24 studies, and nonresponse reasons were not addressed in 24 studies. The most common reasons for studies to be of poor-quality included sample size not justified. Sample is not representative. Nonresponse not addressed. Risk factors not measured correctly.

And methods used were not sufficiently described to repeat them. Studies under the moderate quality did not have a representative sample. Non-responders categories was not addressed. Risk factors were not measured correctly. And methods used were not sufficiently described to allow the study to be replicated by other researchers.The included studies covered three broad categories.

Alcohol and substance use disorders, CMD (depression, anxiety, stress, and suicide risk), socio-cultural aspects, and access to mental health services.Alcohol and substance use disordersFive studies reviewed the consumption of alcohol and opioid. In an ethnographic study conducted in three western districts in Rajasthan, 200 opium users were interviewed. Opium consumption was common among both younger and older males during nonharvest seasons. The common causes for using opium were relief of anxiety related to crop failure due to drought, stress, to get a high, be part of peers, and for increased sexual performance.[16]In a study conducted in Arunachal Pradesh involving a population of more than 5000 individuals, alcohol use was present in 30% and opium use in about 5% adults.[17] Contrary to that study, in Rajasthan, the prevalence of opium use was more in women and socioeconomic factors such as occupation, education, and marital status were associated with opium use.[16] The prevalence of opium use increased with age in both sexes, decreased with increasing education level, and increased with employment. It was observed that wages were used to buy opium.

In the entire region of Chamlang district of Arunachal Pradesh, female substance users were almost half of the males among ST population.[17] Types of substance used were tobacco, alcohol, and opium. Among tobacco users, oral tobacco use was higher than smoking. The prevalence of tobacco use was higher among males, but the prevalence of alcohol use was higher in females, probably due to increased access to homemade rice brew generally prepared by women. This study is unique in terms of finding a strong association with religion and culture with substance use.[18]Alcohol consumption among Paniyas of Wayanad district in Kerala is perceived as a male activity, with many younger people consuming it than earlier. A study concluded that alcohol consumption among them was less of a “choice” than a result of their conditions operating through different mechanisms.

In the past, drinking was traditionally common among elderly males, however the consumption pattern has changed as a significant number of younger men are now drinking. Drinking was clustered within families as fathers and sons drank together. Alcohol is easily accessible as government itself provides opportunities. Some employers would provide alcohol as an incentive to attract Paniya men to work for them.[19]In a study from Jharkhand, several ST community members cited reasons associated with social enhancement and coping with distressing emotions rather than individual enhancement, as a reason for consuming alcohol. Societal acceptance of drinking alcohol and peer pressure, as well as high emotional problems, appeared to be the major etiology leading to higher prevalence of substance dependence in tribal communities.[20] Another study found high life time alcohol use prevalence, and the reasons mentioned were increased poverty, illiteracy, increased stress, and peer pressure.[21] A household survey from Chamlang district of Arunachal Pradesh revealed that there was a strong association between opium use and age, occupation, marital status, religion, and ethnicity among both the sexes of STs, particularly among Singhpho and Khamti.[15] The average age of onset of tobacco use was found to be 16.4 years for smoked and 17.5 years for smokeless forms in one study.[22]Common mental disorders and socio-cultural aspectsSuicide was more common among Idu Mishmi in Roing and Anini districts of Arunachal Pradesh state (14.2%) compared to the urban population in general (0.4%–4.2%).

Suicides were associated with depression, anxiety, alcoholism, and eating disorders. Of all the factors, depression was significantly high in people who attempted suicide.[24] About 5% out of 5007 people from thirty villages comprising ST suffered from CMDs in a study from West Godavari district in rural Andhra Pradesh. CMDs were defined as moderate/severe depression and/or anxiety, stress, and increased suicidal risk. Women had a higher prevalence of depression, but this may be due to the cultural norms, as men are less likely to express symptoms of depression or anxiety, which leads to underreporting. Marital status, education, and age were prominently associated with CMD.[14] In another study, gender, illiteracy, infant mortality in the household, having <3 adults living in the household, large family size with >four children, morbidity, and having two or more life events in the last year were associated with increased prevalence of CMD.[24] Urban and rural ST from the same community of Bhutias of Sikkim were examined, and it was found that the urban population experienced higher perceived stress compared to their rural counterparts.[25] Age, current use of alcohol, poor educational status, marital status, social groups, and comorbidities were the main determinants of tobacco use and nicotine dependence in a study from the Andaman and Nicobar Islands.[22] A study conducted among adolescents in the schools of rural areas of Ranchi district in Jharkhand revealed that about 5% children from the ST communities had emotional symptoms, 9.6% children had conduct problems, 4.2% had hyperactivity, and 1.4% had significant peer problems.[27] A study conducted among the female school teachers in Jharkhand examined the effects of stress, marital status, and ethnicity upon the mental health of school teachers.

The study found that among the three factors namely stress, marital status, and ethnicity, ethnicity was found to affect mental health of the school teachers most. It found a positive relationship between mental health and socioeconomic status, with an inverse relationship showing that as income increased, the prevalence of depression decreased.[28] A study among Ao-Nagas in Nagaland found that 74.6% of the population attributed mental health problems to psycho-social factors and a considerable proportion chose a psychiatrist or psychologist to overcome the problem. However, 15.4% attributed mental disorders to evil spirits. About 47% preferred to seek treatment with a psychiatrist and 25% preferred prayers. Nearly 10.6% wanted to seek the help of both the psychiatrist and prayer group and 4.4% preferred traditional healers.[28],[29] The prevalence of Down syndrome among the ST in Chikhalia in Barwani district of Madhya Pradesh was higher than that reported in overall India.

Three-fourth of the children were the first-born child. None of the parents of children with Down syndrome had consanguineous marriage or a history of Down syndrome, intellectual disability, or any other neurological disorder such as cerebral palsy and epilepsy in preceding generations. It is known that tribal population is highly impoverished and disadvantaged in several ways and suffer proportionately higher burden of nutritional and genetic disorders, which are potential factors for Down syndrome.[30]Access to mental health-care servicesIn a study in Ranchi district of Jharkhand, it was found that most people consulted faith healers rather than qualified medical practitioners. There are few mental health services in the regions.[31] Among ST population, there was less reliance and belief in modern medicine, and it was also not easily accessible, thus the health-care systems must be more holistic and take care of cultural and local health practices.[32]The Systematic Medical Appraisal, Referral and Treatment (SMART) Mental Health project was implemented in thirty ST villages in West Godavari District of Andhra Pradesh. The key objectives were to use task sharing, training of primary health workers, implementing evidence-based clinical decision support tools on a mobile platform, and providing mental health services to rural population.

The study included 238 adults suffering from CMD. During the intervention period, 12.6% visited the primary health-care doctors compared to only 0.8% who had sought any care for their mental disorders prior to the intervention. The study also found a significant reduction in the depression and anxiety scores at the end of intervention and improvements in stigma perceptions related to mental health.[14] A study in Gudalur and Pandalur Taluks of Nilgiri district from Tamil Nadu used low cost task shifting by providing community education and identifying and referring individuals with psychiatric problems as effective strategies for treating mental disorders in ST communities. Through the program, the health workers established a network within the village, which in turn helped the patients to interact with them freely. Consenting patients volunteered at the educational sessions to discuss their experience about the effectiveness of their treatment.

Community awareness programs altered knowledge and attitudes toward mental illness in the community.[33] A study in Nilgiri district, Tamil Nadu, found that the community had been taking responsibility of the patients with the system by providing treatment closer to home without people having to travel long distances to access care. Expenses were reduced by subsidizing the costs of medicine and ensuring free hospital admissions and referrals to the people.[34] A study on the impact of gender, socioeconomic status, and age on mental health of female factory workers in Jharkhand found that the ST women were more likely to face stress and hardship in life due to diverse economic and household responsibilities, which, in turn, severely affected their mental health.[35] Prevalence of mental health morbidity in a study from the Sunderbans delta found a positive relation with psycho-social stressors and poor quality of life. The health system in that remote area was largely managed by “quack doctors” and faith healers. Poverty, illiteracy, and detachment from the larger community helped reinforce superstitious beliefs and made them seek both mental and physical health care from faith healers.[36] In a study among students, it was found that children had difficulties in adjusting to both ethnic and mainstream culture.[27] Low family income, inadequate housing, poor sanitation, and unhealthy and unhygienic living conditions were some environmental factors contributing to poor physical and mental growth of children. It was observed that children who did not have such risk factors maintained more intimate relations with the family members.

Children belonging to the disadvantaged environment expressed their verbal, emotional need, blame, and harm avoidances more freely than their counterparts belonging to less disadvantaged backgrounds. Although disadvantaged children had poor interfamilial interaction, they had better relations with the members outside family, such as peers, friends, and neighbors.[37] Another study in Jharkhand found that epilepsy was higher among ST patients compared to non-ST patients.[31] Most patients among the ST are irregular and dropout rates are higher among them than the non-ST patients. Urbanization per se exerted no adverse influence on the mental health of a tribal community, provided it allowed preservation of ethnic and cultural practices. Women in the ST communities were less vulnerable to mental illness than men. This might be a reflection of their increased responsibilities and enhanced gender roles that are characteristic of women in many ST communities.[38] Data obtained using culturally relevant scales revealed that relocated Sahariya suffer a lot of mental health problems, which are partially explained by livelihood and poverty-related factors.

The loss of homes and displacement compromise mental health, especially the positive emotional well-being related to happiness, life satisfaction, optimism for future, and spiritual contentment. These are often not overcome even with good relocation programs focused on material compensation and livelihood re-establishment.[39] Discussion This systematic review is to our knowledge the first on mental health of ST population in India. Few studies on the mental health of ST were available. All attempts including hand searching were made to recover both published peer-reviewed papers and reports available on the website. Though we searched gray literature, it may be possible that it does not capture all articles.

Given the heterogeneity of the papers, it was not possible to do a meta-analysis, so a narrative review was done.The quality of the studies was assessed by CASP. The assessment shows that the research conducted on mental health of STs needs to be carried out more effectively. The above mentioned gaps need to be filled in future research by considering the resources effectively while conducting the studies. Mental and substance use disorders contribute majorly to the health disparities. To address this, one needs to deliver evidence-based treatments, but it is important to understand how far these interventions for the indigenous populations can incorporate cultural practices, which are essential for the development of mental health services.[30] Evidence has shown a disproportionate burden of suicide among indigenous populations in national and regional studies, and a global and systematic investigation of this topic has not been undertaken to date.

Previous reviews of suicide epidemiology among indigenous populations have tended to be less comprehensive or not systematic, and have often focused on subpopulations such as youth, high-income countries, or regions such as Oceania or the Arctic.[46] The only studies in our review which provided data on suicide were in Idu Mishmi, an isolated tribal population of North-East India, and tribal communities from Sunderban delta.[24],[37] Some reasons for suicide in these populations could be the poor identification of existing mental disorders, increased alcohol use, extreme poverty leading to increased debt and hopelessness, and lack of stable employment opportunities.[24],[37] The traditional consumption pattern of alcohol has changed due to the reasons associated with social enhancement and coping with distressing emotions rather than individual enhancement.[19],[20]Faith healers play a dominant role in treating mental disorders. There is less awareness about mental health and available mental health services and even if such knowledge is available, access is limited due to remoteness of many of these villages, and often it involves high out-of-pocket expenditure.[35] Practitioners of modern medicine can play a vital role in not only increasing awareness about mental health in the community, but also engaging with faith healers and traditional medicine practitioners to help increase their capacity to identify and manage CMDs that do not need medications and can be managed through simple “talk therapy.” Knowledge on symptoms of severe mental disorders can also help such faith healers and traditional medicine practitioners to refer cases to primary care doctors or mental health professionals.Remote settlements make it difficult for ST communities to seek mental health care. Access needs to be increased by using solutions that use training of primary health workers and nonphysician health workers, task sharing, and technology-enabled clinical decision support tools.[3] The SMART Mental Health project was delivered in the tribal areas of Andhra Pradesh using those principles and was found to be beneficial by all stakeholders.[14]Given the lack of knowledge about mental health problems among these communities, the government and nongovernmental organizations should collect and disseminate data on mental disorders among the ST communities. More research funding needs to be provided and key stakeholders should be involved in creating awareness both in the community and among policy makers to develop more projects for ST communities around mental health. Two recent meetings on tribal mental health – Round Table Meeting on Mental Health of ST Populations organized by the George Institute for Global Health, India, in 2017,[51] and the First National Conference on Tribal Mental Health organized by the Indian Psychiatric Society in Bhubaneswar in 2018 – have identified some key areas of research priority for mental health in ST communities.

A national-level policy on mental health of tribal communities or population is advocated which should be developed in consultation with key stakeholders. The Indian Psychiatric Society can play a role in coordinating research activities with support of the government which can ensure regular monitoring and dissemination of the research impact to the tribal communities. There is a need to understand how mental health symptoms are perceived in different ST communities and investigate the healing practices associated with distress/disaster/death/loss/disease. This could be done in the form of cross-sectional or cohort studies to generate proper evidence which could also include the information on prevalence, mental health morbidity, and any specific patterns associated with a specific disorder. Future research should estimate the prevalence of mental disorders in different age groups and gender, risk factors, and the influence of modernization.

Studies should develop a theoretical model to understand mental disorders and promote positive mental health within ST communities. Studies should also look at different ST communities as cultural differences exist across them, and there are also differences in socioeconomic status which impact on ability to access care.Research has shown that the impact and the benefits are amplified when research is driven by priorities that are identified by indigenous communities and involve their active participation. Their knowledge and perspectives are incorporated in processes and findings. Reporting of findings is meaningful to the communities. And indigenous groups and other key stakeholders are engaged from the outset.[47] Future research in India on ST communities should also adhere to these broad principles to ensure relevant and beneficial research, which have direct impact on the mental health of the ST communities.There is also a need to update literature related to mental health of ST population continuously.

Develop culturally appropriate validated instruments to measure mental morbidity relevant to ST population. And use qualitative research to investigate the perceptions and barriers for help-seeking behavior.[48] Conclusion The current review helps not only to collate the existing literature on the mental health of ST communities but also identify gaps in knowledge and provide some indications about the type of research that should be funded in future.Financial support and sponsorshipNil.Conflicts of interestThere are no conflicts of interest. References 1.Gururaj G, Girish N, Isaac MK. Mental. Neurological and Substance abuse disorders.

Strategies towards a systems approach. In. Burden of Disease in India. Equitable development – Healthy future New Delhi, India. National Commission on Macroeconomics and Health.

Ministry of Health and Family Welfare, Government of India. 2005. 2.Math SB, Srinivasaraju R. Indian Psychiatric epidemiological studies https://martello-halfmarathon.org.uk/what-to-do-on-the-day/. Learning from the past.

Indian J Psychiatry 2010;52:S95-103. 3.Tewari A, Kallakuri S, Devarapalli S, Jha V, Patel A, Maulik PK. Process evaluation of the systematic medical appraisal, referral and treatment (SMART) mental health project in rural India. BMC Psychiatry 2017;17:385. 4.Ministry of Tribal Affairs, Government of India.

Report of the High Level Committee on Socio-economic, Health and Educational Status of Tribal Communities of India. New Delhi. Government of India. 2014. 5.Office of the Registrar General and Census Commissioner, Census of India.

New Delhi. Office of the Registrar General and Census Commissioner. 2011. 6.International Institute for Population Sciences and ICF. National Family Health Survey (NFHS-4), 2015-16.

India, Mumbai. International Institute for Population Sciences. 2017. 7.World Health Organization. The World Health Report 2001-Mental Health.

New Understanding, New Hope. Geneva, Switzerland. World Health Organization. 2001. 8.Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al.

Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004;291:2581-90. 9.Ministry of Health and Family Welfare, Government of India and Ministry of Tribal Affairs, Report of the Expert Committee on Tribal Health. Tribal Health in India – Bridging the Gap and a Roadmap for the Future. New Delhi.

Government of India. 2013. 10.Government of India, Rural Health Statistics 2016-17. Ministry of Health and Family Welfare Statistics Division. 2017.

11.Ormel J, VonKorff M, Ustun TB, Pini S, Korten A, Oldehinkel T. Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA 1994;272:1741-8. 12.Thornicroft G, Brohan E, Rose D, Sartorius N, Leese M, INDIGO Study Group.

Global pattern of experienced and anticipated discrimination against people with schizophrenia. A cross-sectional survey. Lancet 2009;373:408-15. 13.Armstrong G, Kermode M, Raja S, Suja S, Chandra P, Jorm AF. A mental health training program for community health workers in India.

Impact on knowledge and attitudes. Int J Ment Health Syst 2011;5:17. 14.Maulik PK, Kallakuri S, Devarapalli S, Vadlamani VS, Jha V, Patel A. Increasing use of mental health services in remote areas using mobile technology. A pre-post evaluation of the SMART Mental Health project in rural India.

J Global Health 2017;7:1-13. 15.16.Ganguly KK, Sharma HK, Krishnamachari KA. An ethnographic account of opium consumers of Rajasthan (India). Socio-medical perspective. Addiction 1995;90:9-12.

17.Chaturvedi HK, Mahanta J. Sociocultural diversity and substance use pattern in Arunachal Pradesh, India. Drug Alcohol Depend 2004;74:97-104. 18.Chaturvedi HK, Mahanta J, Bajpai RC, Pandey A. Correlates of opium use.

Retrospective analysis of a survey of tribal communities in Arunachal Pradesh, India. BMC Public Health 2013;13:325. 19.Mohindra KS, Narayana D, Anushreedha SS, Haddad S. Alcohol use and its consequences in South India. Views from a marginalised tribal population.

Drug Alcohol Depend 2011;117:70-3. 20.Sreeraj VS, Prasad S, Khess CR, Uvais NA. Reasons for substance use. A comparative study of alcohol use in tribals and non-tribals. Indian J Psychol Med 2012;34:242-6.

[PUBMED] [Full text] 21.Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders. Findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1575-86. 22.Janakiram C, Joseph J, Vasudevan S, Taha F, DeepanKumar CV, Venkitachalam R.

Prevalence and dependancy of tobacco use in an indigenous population of Kerala, India. Oral Hygiene and Health 2016;4:1 23.Manimunda SP, Benegal V, Sugunan AP, Jeemon P, Balakrishna N, Thennarusu K, et al. Tobacco use and nicotine dependency in a cross-sectional representative sample of 18,018 individuals in Andaman and Nicobar Islands, India. BMC Public Health 2012;12:515. 24.Singh PK, Singh RK, Biswas A, Rao VR.

High rate of suicide attempt and associated psychological traits in an isolated tribal population of North-East India. J Affect Dis 2013;151:673-8. 25.Sushila J. Perception of Illness and Health Care among Bhils. A Study of Udaipur District in Southern Rajasthan.

2005. 26.Sobhanjan S, Mukhopadhyay B. Perceived psychosocial stress and cardiovascular risk. Observations among the Bhutias of Sikkim, India. Stress Health 2008;24:23-34.

27.Ali A, Eqbal S. Mental Health status of tribal school going adolescents. A study from rural community of Ranchi, Jharkhand. Telangana J Psychiatry 2016;2:38-41. 28.Diwan R.

Stress and mental health of tribal and non tribal female school teachers in Jharkhand, India. Int J Sci Res Publicat 2012;2:2250-3153. 29.Longkumer I, Borooah PI. Knowledge about attitudes toward mental disorders among Nagas in North East India. IOSR J Humanities Soc Sci 2013;15:41-7.

30.Lakhan R, Kishore MT. Down syndrome in tribal population in India. A field observation. J Neurosci Rural Pract 2016;7:40-3. [PUBMED] [Full text] 31.Nizamie HS, Akhtar S, Banerjee S, Goyal N.

Health care delivery model in epilepsy to reduce treatment gap. WHO study from a rural tribal population of India. Epilepsy Res Elsevier 2009;84:146-52. 32.Prabhakar H, Manoharan R. The Tribal Health Initiative model for healthcare delivery.

A clinical and epidemiological approach. Natl Med J India 2005;18:197-204. 33.Nimgaonkar AU, Menon SD. A task shifting mental health program for an impoverished rural Indian community. Asian J Psychiatr 2015;16:41-7.

34.Yalsangi M. Evaluation of a Community Mental Health Programme in a Tribal Area- South India. Achutha Menon Centre For Health Sciences Studies, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Working Paper No 12. 2012. 35.Tripathy P, Nirmala N, Sarah B, Rajendra M, Josephine B, Shibanand R, et al.

Effect of a participatory intervention with women's groups on birth outcomes and maternal depression in Jharkhand and Orissa, India. A cluster-randomised controlled trial. Lancet 2010;375:1182-92. 36.Aparajita C, Anita KM, Arundhati R, Chetana P. Assessing Social-support network among the socio culturally disadvantaged children in India.

Early Child Develop Care 1996;121:37-47. 37.Chowdhury AN, Mondal R, Brahma A, Biswas MK. Eco-psychiatry and environmental conservation. Study from Sundarban Delta, India. Environ Health Insights 2008;2:61-76.

38.Jeffery GS, Chakrapani U. Eco-psychiatry and Environmental Conservation. Study from Sundarban Delta, India. Working Paper- Research Gate.net. September, 2016.

39.Ozer S, Acculturation, adaptation, and mental health among Ladakhi College Students a mixed methods study of an indigenous population. J Cross Cultl Psychol 2015;46:435-53. 40.Giri DK, Chaudhary S, Govinda M, Banerjee A, Mahto AK, Chakravorty PK. Utilization of psychiatric services by tribal population of Jharkhand through community outreach programme of RINPAS. Eastern J Psychiatry 2007;10:25-9.

41.Nandi DN, Banerjee G, Chowdhury AN, Banerjee T, Boral GC, Sen B. Urbanization and mental morbidity in certain tribal communities in West Bengal. Indian J Psychiatry 1992;34:334-9. [PUBMED] [Full text] 42.Hackett RJ, Sagdeo D, Creed FH. The physical and social associations of common mental disorder in a tribal population in South India.

Soc Psychiatry Psychiatr Epidemiol 2007;42:712-5. 43.Raina SK, Raina S, Chander V, Grover A, Singh S, Bhardwaj A. Development of a cognitive screening instrument for tribal elderly population of Himalayan region in northern India. J Neurosci Rural Pract 2013;4:147-53. [PUBMED] [Full text] 44.Raina SK, Raina S, Chander V, Grover A, Singh S, Bhardwaj A.

Identifying risk for dementia across populations. A study on the prevalence of dementia in tribal elderly population of Himalayan region in Northern India. Ann Indian Acad Neurol 2013;16:640-4. [PUBMED] [Full text] 45.Raina SK, Chander V, Raina S, Kumar D. Feasibility of using everyday abilities scale of India as alternative to mental state examination as a screen in two-phase survey estimating the prevalence of dementia in largely illiterate Indian population.

Indian J Psychiatry 2016;58:459-61. [PUBMED] [Full text] 46.Diwan R. Mental health of tribal male-female factory workers in Jharkhand. IJAIR 2012;2278:234-42. 47.Banerjee T, Mukherjee SP, Nandi DN, Banerjee G, Mukherjee A, Sen B, et al.

Psychiatric morbidity in an urbanized tribal (Santal) community - A field survey. Indian J Psychiatry 1986;28:243-8. [PUBMED] [Full text] 48.Leske S, Harris MG, Charlson FJ, Ferrari AJ, Baxter AJ, Logan JM, et al. Systematic review of interventions for Indigenous adults with mental and substance use disorders in Australia, Canada, New Zealand and the United States. Aust N Z J Psychiatry 2016;50:1040-54.

49.Pollock NJ, Naicker K, Loro A, Mulay S, Colman I. Global incidence of suicide among Indigenous peoples. A systematic review. BMC Med 2018;16:145. 50.Silburn K, et al.

Evaluation of the Cooperative Research Centre for Aboriginal Health (Australian institute for primary care, trans.). Melbourne. LaTrobe University. 2010. 51.

Correspondence Address:S V. Siddhardh Kumar DevarapalliGeorge Institute for Global Health, Plot No. 57, Second Floor, Corporation Bank Building, Nagarjuna Circle, Punjagutta, Hyderabad - 500 082, Telangana IndiaSource of Support. None, Conflict of Interest. NoneDOI.

10.4103/psychiatry.IndianJPsychiatry_136_19 Figures [Figure 1] Tables [Table 1], [Table 2].

How to https://hbmoore.com/blog/ cite this article:Singh OP what i should buy with cipro. Psychiatry research in India. Closing the research gap what i should buy with cipro. Indian J Psychiatry 2020;62:615-6Research is an important aspect of the growth and development of medical science. Research in India in general and medical what i should buy with cipro research in particular is always being criticized for lack of innovation and originality required for the delivery of health services suitable to Indian conditions.

Even the Indian Council of Medical Research (ICMR) which is a centrally funded frontier organization for conducting medical research couldn't avert criticism. It has been criticized heavily for not producing quality research papers which are pioneering, ground breaking, or pragmatic solutions for health issues plaguing India. In the words of a leading daily, The ICMR could not even list one practical application of its hundreds of research papers what i should buy with cipro published in various national and international research journals which helped cure any disease, or diagnose it with better accuracy or in less time, or even one new basic, applied or clinical research or innovation that opened a new frontier of scientific knowledge.[1]This clearly indicates that the health research output of ICMR is not up to the mark and is not commensurate with the magnitude of the disease burden in India. According to the 12th Plan Report, the country contributes to a fifth of the world's share of diseases. The research conducted elsewhere may not be generalized to the Indian population owing to differences in what i should buy with cipro biology, health-care systems, health practices, culture, and socioeconomic standards.

Questions which are pertinent and specific to the Indian context may not be answered and will remain understudied. One of the vital elements in improving this situation is the need for relevant research base that would equip policymakers to take informed health policy decisions.The Parliamentary Standing Committee on Health and Family Welfare in the 100th report on Demand for Grants (2017–2018) of the Department of Health Research observed that “the biomedical research output needs to be augmented substantially to cater to the health challenges faced by the country.”[1]Among the various reasons, lack of fund, infrastructure, and resources is the prime cause which is glaringly evident from the inadequate budget allocation for biomedical research. While ICMR has a budget of 232 million dollars per year on health research, it is zilch in comparison to the annual budget expenditure of the National what i should buy with cipro Institute of Health, USA, on biomedical research which is 32 billion dollars.The lacuna of quality research is not merely due to lack of funds. There are other important issues which need to be considered and sorted out to end the status quo. Some of the factors which need our immediate attention what i should buy with cipro are:Lack of research training and teachingImproper allocation of research facilitiesLack of information about research work happening globallyLack of promotion, motivation, commitment, and passion in the field of researchClinicians being overburdened with patientsLack of collaboration between medical colleges and established research institutesLack of continuity of research in successive batches of postgraduate (PG) students, leading to wastage of previous research and resourcesDifficulty in the application of basic biomedical research into pragmatic intervention solutions due to lack of interdisciplinary technological support/collaboration between basic scientists, clinicians, and technological experts.Majority of the biomedical research in India are conducted in medical institutions.

The majority of these are done as thesis submission for fulfillment of the requirement of PG degree. From 2015 onward, publication of papers had been what i should buy with cipro made an obligatory requirement for promotion of faculty to higher posts. Although it offered a unique opportunity for training of residents and stimulus for research, it failed to translate into production of quality research work as thesis was limited by time and it had to be done with other clinical and academic duties.While the top four medical colleges, namely AIIMS, New Delhi. PGIMER, Chandigarh. CMC, Vellore what i should buy with cipro.

And SGIMS, Lucknow are among the top ten medical institutions in terms of publication in peer-reviewed journals, around 332 (57.3%) medical colleges have no research paper published in a decade between 2004 and 2014.[2]The research in psychiatry is realistically dominated by major research institutes which are doing commendable work, but there is a substantial lack of contemporary research originating from other centers. Dr. Chittaranjan Andrade (NIMHANS, Bengaluru) and Dr. K Jacob (CMC, Vellore) recently figured in the list of top 2% psychiatry researchers in the world from India in psychiatry.[3] Most of the research conducted in the field of psychiatry are limited to caregivers' burden, pathways of care, and other topics which can be done in limited resources available to psychiatry departments. While all these areas of work are important in providing proper care and treatment, there is overabundance of research in these areas.The Government of India is aggressively looking forward to enhancing the quality of research and is embarking on an ambitious project of purchasing all major journals and providing free access to universities across the country.

The India Genome Project started in January, 2020, is a good example of collaboration. While all these actions are laudable, a lot more needs to be done. Following are some measures which will reduce the gap:Research proposals at the level of protocol can be guided and mentored by institutes. Academic committees of different zones and journals can help in this endeavorBreaking the cubicles by establishing a collaboration between medical colleges and various institutes. While there is a lack of resources available in individual departments, there are universities and institutes with excellent infrastructure.

They are not aware of the requirements of the field of psychiatry and research questions. Creation of an alliance will enhance the quality of research work. Some of such institutes include Centre for Neuroscience, Indian Institute of Science, Bengaluru. CSIR-Institute of Genomics and Integrative Biology, New Delhi. And National Institute of Biomedical Genomics, KalyaniInitiation and establishment of interactive and stable relationships between basic scientists and clinical and technological experts will enhance the quality of research work and will lead to translation of basic biomedical research into real-time applications.

For example, work on artificial intelligence for mental health. Development of Apps by IITs. Genome India Project by the Government of India, genomic institutes, and social science and economic institutes working in the field of various aspects of mental healthUtilization of underutilized, well-equipped biotechnological labs of nonmedical colleges for furthering biomedical researchMedical colleges should collaborate with various universities which have labs providing testing facilities such as spectroscopy, fluoroscopy, gamma camera, scintigraphy, positron emission tomography, single photon emission computed tomography, and photoacoustic imagingCreating an interactive, interdepartmental, intradepartmental, and interinstitutional partnershipBy developing a healthy and ethical partnership with industries for research and development of new drugs and interventions.Walking the talk – the psychiatric fraternity needs to be proactive and rather than lamenting about the lack of resource, we should rise to the occasion and come out with innovative and original research proposals. With the implementation of collaborative approach, we can not only enhance and improve the quality of our research but to an extent also mitigate the effects of resource crunch and come up as a leader in the field of biomedical research. References 1.2.Nagoba B, Davane M.

Current status of medical research in India. Where are we?. Walawalkar Int Med J 2017;4:66-71. 3.Ioannidis JP, Boyack KW, Baas J. Updated science-wide author databases of standardized citation indicators.

PLoS Biol 2020;18:e3000918. Correspondence Address:Dr. Om Prakash SinghAA 304, Ashabari Apartments, O/31, Baishnabghata, Patuli Township, Kolkata - 700 094, West Bengal IndiaSource of Support. None, Conflict of Interest. NoneDOI.

10.4103/indianjpsychiatry.indianjpsychiatry_1362_2Abstract Background. The burden of mental illness among the scheduled tribe (ST) population in India is not known clearly.Aim. The aim was to identify and appraise mental health research studies on ST population in India and collate such data to inform future research.Materials and Methods. Studies published between January 1980 and December 2018 on STs by following exclusion and inclusion criteria were selected for analysis. PubMed, PsychINFO, Embase, Sociofile, Cinhal, and Google Scholar were systematically searched to identify relevant studies.

Quality of the included studies was assessed using an appraisal tool to assess the quality of cross-sectional studies and Critical Appraisal Checklist developed by Critical Appraisal Skills Programme. Studies were summarized and reported descriptively.Results. Thirty-two relevant studies were found and included in the review. Studies were categorized into the following three thematic areas. Alcohol and substance use disorders, common mental disorders and sociocultural aspects, and access to mental health-care services.

Sociocultural factors play a major role in understanding and determining mental disorders.Conclusion. This study is the first of its kind to review research on mental health among the STs. Mental health research conducted among STs in India is limited and is mostly of low-to-moderate quality. Determinants of poor mental health and interventions for addressing them need to be studied on an urgent basis.Keywords. India, mental health, scheduled tribesHow to cite this article:Devarapalli S V, Kallakuri S, Salam A, Maulik PK.

Mental health research on scheduled tribes in India. Indian J Psychiatry 2020;62:617-30 Introduction Mental health is a highly neglected area particularly in low and middle-income countries (LMIC). Data from community-based studies showed that about 10% of people suffer from common mental disorders (CMDs) such as depression, anxiety, and somatic complaints.[1] A systematic review of epidemiological studies between 1960 and 2009 in India reported that about 20% of the adult population in the community are affected by psychiatric disorders in the community, ranging from 9.5 to 103/1000 population, with differences in case definitions, and methods of data collection, accounting for most of the variation in estimates.[2]The scheduled tribes (ST) population is a marginalized community and live in relative social isolation with poorer health indices compared to similar nontribal populations.[3] There are an estimated 90 million STs or Adivasis in India.[4] They constitute 8.6% of the total Indian population. The distribution varies across the states and union territories of India, with the highest percentage in Lakshadweep (94.8%) followed by Mizoram (94.4%). In northeastern states, they constitute 65% or more of the total population.[5] The ST communities are identified as culturally or ethnographically unique by the Indian Constitution.

They are populations with poorer health indicators and fewer health-care facilities compared to non-ST rural populations, even when within the same state, and often live in demarcated geographical areas known as ST areas.[4]As per the National Family Health Survey, 2015–2016, the health indicators such as infant mortality rate (IMR) is 44.4, under five mortality rate (U5MR) is 57.2, and anemia in women is 59.8 for STs – one of the most disadvantaged socioeconomic groups in India, which are worse compared to other populations where IMR is 40.7, U5MR is 49.7, and anemia in women among others is 53.0 in the same areas.[6] Little research is available on the health of ST population. Tribal mental health is an ignored and neglected area in the field of health-care services. Further, little data are available about the burden of mental disorders among the tribal communities. Health research on tribal populations is poor, globally.[7] Irrespective of the data available, it is clear that they have worse health indicators and less access to health facilities.[8] Even less is known about the burden of mental disorders in ST population. It is also found that the traditional livelihood system of the STs came into conflict with the forces of modernization, resulting not only in the loss of customary rights over the livelihood resources but also in subordination and further, developing low self-esteem, causing great psychological stress.[4] This community has poor health infrastructure and even less mental health resources, and the situation is worse when compared to other communities living in similar areas.[9],[10]Only 15%–25% of those affected with mental disorders in LMICs receive any treatment for their mental illness,[11] resulting in a large “treatment gap.”[12] Treatment gaps are more in rural populations,[13] especially in ST communities in India, which have particularly poor infrastructure and resources for health-care delivery in general, and almost no capacity for providing mental health care.[14]The aim of this systematic review was to explore the extent and nature of mental health research on ST population in India and to identify gaps and inform future research.

Materials and Methods Search strategyWe searched major databases (PubMed, PsychINFO, Embase, Sociofile, Cinhal, and Google Scholar) and made hand searches from January 1980 to December 2018 to identify relevant literature. Hand search refers to searching through medical journals which are not indexed in the major electronic databases such as Embase, for instance, searching for Indian journals in IndMed database as most of these journals are not available in major databases. Physical search refers to searching the journals that were not available online or were not available online during the study years. We used relevant Medical Subject Heading and key terms in our search strategy, as follows. €œMental health,” “Mental disorders,” “Mental illness,” “Psychiatry,” “Scheduled Tribe” OR “Tribe” OR “Tribal Population” OR “Indigenous population,” “India,” “Psych*” (Psychiatric, psychological, psychosis).Inclusion criteriaStudies published between January 1980 and December 2018 were included.

Studies on mental disorders were included only when they focused on ST population. Both qualitative and quantitative studies on mental disorders of ST population only were included in the analysis.Exclusion criteriaStudies without any primary data and which are merely overviews and commentaries and those not focused on ST population were excluded from the analysis.Data management and analysisTwo researchers (SD and SK) initially screened the title and abstract of each record to identify relevant papers and subsequently screened full text of those relevant papers. Any disagreements between the researchers were resolved by discussion or by consulting with an adjudicator (PKM). From each study, data were extracted on objectives, study design, study population, study duration, interventions (if applicable), outcomes, and results. Quality of the included studies was assessed, independently by three researchers (SD, SK, and AS), using Critical Appraisal Checklist developed by Critical Appraisal Skills Programme (CASP).[15] After a thorough qualitative assessment, all quantitative data were generated and tabulated.

A narrative description of the studies is provided in [Table 1] using some broad categories. Results Search resultsOur search retrieved 2306 records (which included hand-searched articles), of which after removing duplicates, title and abstracts of 2278 records were screened. Of these, 178 studies were deemed as potentially relevant and were reviewed in detail. Finally, we excluded 146 irrelevant studies and 32 studies were included in the review [Figure 1].Quality of the included studiesSummary of quality assessment of the included studies is reported in [Table 2]. Overall, nine studies were of poor quality, twenty were of moderate quality, and three studies were of high quality.

The CASP shows that out of the 32 studies, the sample size of 21 studies was not representative, sample size of 7 studies was not justified, risk factors were not identified in 28 studies, methods used were not sufficiently described to repeat them in 24 studies, and nonresponse reasons were not addressed in 24 studies. The most common reasons for studies to be of poor-quality included sample size not justified. Sample is not representative. Nonresponse not addressed. Risk factors not measured correctly.

And methods used were not sufficiently described to repeat them. Studies under the moderate quality did not have a representative sample. Non-responders categories was not addressed. Risk factors were not measured correctly. And methods used were not sufficiently described to allow the study to be replicated by other researchers.The included studies covered three broad categories.

Alcohol and substance use disorders, CMD (depression, anxiety, stress, and suicide risk), socio-cultural aspects, and access to mental health services.Alcohol and substance use disordersFive studies reviewed the consumption of alcohol and opioid. In an ethnographic study conducted in three western districts in Rajasthan, 200 opium users were interviewed. Opium consumption was common among both younger and older males during nonharvest seasons. The common causes for using opium were relief of anxiety related to crop failure due to drought, stress, to get a high, be part of peers, and for increased sexual performance.[16]In a study conducted in Arunachal Pradesh involving a population of more than 5000 individuals, alcohol use was present in 30% and opium use in about 5% adults.[17] Contrary to that study, in Rajasthan, the prevalence of opium use was more in women and socioeconomic factors such as occupation, education, and marital status were associated with opium use.[16] The prevalence of opium use increased with age in both sexes, decreased with increasing education level, and increased with employment. It was observed that wages were used to buy opium.

In the entire region of Chamlang district of Arunachal Pradesh, female substance users were almost half of the males among ST population.[17] Types of substance used were tobacco, alcohol, and opium. Among tobacco users, oral tobacco use was higher than smoking. The prevalence of tobacco use was higher among males, but the prevalence of alcohol use was higher in females, probably due to increased access to homemade rice brew generally prepared by women. This study is unique in terms of finding a strong association with religion and culture with substance use.[18]Alcohol consumption among Paniyas of Wayanad district in Kerala is perceived as a male activity, with many younger people consuming it than earlier. A study concluded that alcohol consumption among them was less of a “choice” than a result of their conditions operating through different mechanisms.

In the past, drinking was traditionally common among elderly males, however the consumption pattern has changed as a significant number of younger men are now drinking. Drinking was clustered within families as fathers and sons drank together. Alcohol is easily accessible as government itself provides opportunities. Some employers would provide alcohol as an incentive to attract Paniya men to work for them.[19]In a study from Jharkhand, several ST community members cited reasons associated with social enhancement and coping with distressing emotions rather than individual enhancement, as a reason for consuming alcohol. Societal acceptance of drinking alcohol and peer pressure, as well as high emotional problems, appeared to be the major etiology leading to higher prevalence of substance dependence in tribal communities.[20] Another study found high life time alcohol use prevalence, and the reasons mentioned were increased poverty, illiteracy, increased stress, and peer pressure.[21] A household survey from Chamlang district of Arunachal Pradesh revealed that there was a strong association between opium use and age, occupation, marital status, religion, and ethnicity among both the sexes of STs, particularly among Singhpho and Khamti.[15] The average age of onset of tobacco use was found to be 16.4 years for smoked and 17.5 years for smokeless forms in one study.[22]Common mental disorders and socio-cultural aspectsSuicide was more common among Idu Mishmi in Roing and Anini districts of Arunachal Pradesh state (14.2%) compared to the urban population in general (0.4%–4.2%).

Suicides were associated with depression, anxiety, alcoholism, and eating disorders. Of all the factors, depression was significantly high in people who attempted suicide.[24] About 5% out of 5007 people from thirty villages comprising ST suffered from CMDs in a study from West Godavari district in rural Andhra Pradesh. CMDs were defined as moderate/severe depression and/or anxiety, stress, and increased suicidal risk. Women had a higher prevalence of depression, but this may be due to the cultural norms, as men are less likely to express symptoms of depression or anxiety, which leads to underreporting. Marital status, education, and age were prominently associated with CMD.[14] In another study, gender, illiteracy, infant mortality in the household, having <3 adults living in the household, large family size with >four children, morbidity, and having two or more life events in the last year were associated with increased prevalence of CMD.[24] Urban and rural ST from the same community of Bhutias of Sikkim were examined, and it was found that the urban population experienced higher perceived stress compared to their rural counterparts.[25] Age, current use of alcohol, poor educational status, marital status, social groups, and comorbidities were the main determinants of tobacco use and nicotine dependence in a study from the Andaman and Nicobar Islands.[22] A study conducted among adolescents in the schools of rural areas of Ranchi district in Jharkhand revealed that about 5% children from the ST communities had emotional symptoms, 9.6% children had conduct problems, 4.2% had hyperactivity, and 1.4% had significant peer problems.[27] A study conducted among the female school teachers in Jharkhand examined the effects of stress, marital status, and ethnicity upon the mental health of school teachers.

The study found that among the three factors namely stress, marital status, and ethnicity, ethnicity was found to affect mental health of the school teachers most. It found a positive relationship between mental health and socioeconomic status, with an inverse relationship showing that as income increased, the prevalence of depression decreased.[28] A study among Ao-Nagas in Nagaland found that 74.6% of the population attributed mental health problems to psycho-social factors and a considerable proportion chose a psychiatrist or psychologist to overcome the problem. However, 15.4% attributed mental disorders to evil spirits. About 47% preferred to seek treatment with a psychiatrist and 25% preferred prayers. Nearly 10.6% wanted to seek the help of both the psychiatrist and prayer group and 4.4% preferred traditional healers.[28],[29] The prevalence of Down syndrome among the ST in Chikhalia in Barwani district of Madhya Pradesh was higher than that reported in overall India.

Three-fourth of the children were the first-born child. None of the parents of children with Down syndrome had consanguineous marriage or a history of Down syndrome, intellectual disability, or any other neurological disorder such as cerebral palsy and epilepsy in preceding generations. It is known that tribal population is highly impoverished and disadvantaged in several ways and suffer proportionately higher burden of nutritional and genetic disorders, which are potential factors for Down syndrome.[30]Access to mental health-care servicesIn a study in Ranchi district of Jharkhand, it was found that most people consulted faith healers rather than qualified medical practitioners. There are few mental health services in the regions.[31] Among ST population, there was less reliance and belief in modern medicine, and it was also not easily accessible, thus the health-care systems must be more holistic and take care of cultural and local health practices.[32]The Systematic Medical Appraisal, Referral and Treatment (SMART) Mental Health project was implemented in thirty ST villages in West Godavari District of Andhra Pradesh. The key objectives were to use task sharing, training of primary health workers, implementing evidence-based clinical decision support tools on a mobile platform, and providing mental health services to rural population.

The study included 238 adults suffering from CMD. During the intervention period, 12.6% visited the primary health-care doctors compared to only 0.8% who had sought any care for their mental disorders prior to the intervention. The study also found a significant reduction in the depression and anxiety scores at the end of intervention and improvements in stigma perceptions related to mental health.[14] A study in Gudalur and Pandalur Taluks of Nilgiri district from Tamil Nadu used low cost task shifting by providing community education and identifying and referring individuals with psychiatric problems as effective strategies for treating mental disorders in ST communities. Through the program, the health workers established a network within the village, which in turn helped the patients to interact with them freely. Consenting patients volunteered at the educational sessions to discuss their experience about the effectiveness of their treatment.

Community awareness programs altered knowledge and attitudes toward mental illness in the community.[33] A study in Nilgiri district, Tamil Nadu, found that the community had been taking responsibility of the patients with the system by providing treatment closer to home without people having to travel long distances to access care. Expenses were reduced by subsidizing the costs of medicine and ensuring free hospital admissions and referrals to the people.[34] A study on the impact of gender, socioeconomic status, and age on mental health of female factory workers in Jharkhand found that the ST women were more likely to face stress and hardship in life due to diverse economic and household responsibilities, which, in turn, severely affected their mental health.[35] Prevalence of mental health morbidity in a study from the Sunderbans delta found a positive relation with psycho-social stressors and poor quality of life. The health system in that remote area was largely managed by “quack doctors” and faith healers. Poverty, illiteracy, and detachment from the larger community helped reinforce superstitious beliefs and made them seek both mental and physical health care from faith healers.[36] In a study among students, it was found that children had difficulties in adjusting to both ethnic and mainstream culture.[27] Low family income, inadequate housing, poor sanitation, and unhealthy and unhygienic living conditions were some environmental factors contributing to poor physical and mental growth of children. It was observed that children who did not have such risk factors maintained more intimate relations with the family members.

Children belonging to the disadvantaged environment expressed their verbal, emotional need, blame, and harm avoidances more freely than their counterparts belonging to less disadvantaged backgrounds. Although disadvantaged children had poor interfamilial interaction, they had better relations with the members outside family, such as peers, friends, and neighbors.[37] Another study in Jharkhand found that epilepsy was higher among ST patients compared to non-ST patients.[31] Most patients among the ST are irregular and dropout rates are higher among them than the non-ST patients. Urbanization per se exerted no adverse influence on the mental health of a tribal community, provided it allowed preservation of ethnic and cultural practices. Women in the ST communities were less vulnerable to mental illness than men. This might be a reflection of their increased responsibilities and enhanced gender roles that are characteristic of women in many ST communities.[38] Data obtained using culturally relevant scales revealed that relocated Sahariya suffer a lot of mental health problems, which are partially explained by livelihood and poverty-related factors.

The loss of homes and displacement compromise mental health, especially the positive emotional well-being related to happiness, life satisfaction, optimism for future, and spiritual contentment. These are often not overcome even with good relocation programs focused on material compensation and livelihood re-establishment.[39] Discussion This systematic review is to our knowledge the first on mental health of ST population in India. Few studies on the mental health of ST were available. All attempts including hand searching were made to recover both published peer-reviewed papers and reports available on the website. Though we searched gray literature, it may be possible that it does not capture all articles.

Given the heterogeneity of the papers, it was not possible to do a meta-analysis, so a narrative review was done.The quality of the studies was assessed by CASP. The assessment shows that the research conducted on mental health of STs needs to be carried out more effectively. The above mentioned gaps need to be filled in future research by considering the resources effectively while conducting the studies. Mental and substance use disorders contribute majorly to the health disparities. To address this, one needs to deliver evidence-based treatments, but it is important to understand how far these interventions for the indigenous populations can incorporate cultural practices, which are essential for the development of mental health services.[30] Evidence has shown a disproportionate burden of suicide among indigenous populations in national and regional studies, and a global and systematic investigation of this topic has not been undertaken to date.

Previous reviews of suicide epidemiology among indigenous populations have tended to be less comprehensive or not systematic, and have often focused on subpopulations such as youth, high-income countries, or regions such as Oceania or the Arctic.[46] The only studies in our review which provided data on suicide were in Idu Mishmi, an isolated tribal population of North-East India, and tribal communities from Sunderban delta.[24],[37] Some reasons for suicide in these populations could be the poor identification of existing mental disorders, increased alcohol use, extreme poverty leading to increased debt and hopelessness, and lack of stable employment opportunities.[24],[37] The traditional consumption pattern of alcohol has changed due to the reasons associated with social enhancement and coping with distressing emotions rather than individual enhancement.[19],[20]Faith healers play a dominant role in treating mental disorders. There is less awareness about mental health and available mental health services and even if such knowledge is available, access is limited due to remoteness of many of these villages, and often it involves high out-of-pocket expenditure.[35] Practitioners of modern medicine can play a vital role in not only increasing awareness about mental health in the community, but also engaging with faith healers and traditional medicine practitioners to help increase their capacity to identify and manage CMDs that do not need medications and can be managed through simple “talk therapy.” Knowledge on symptoms of severe mental disorders can also help such faith healers and traditional medicine practitioners to refer cases to primary care doctors or mental health professionals.Remote settlements make it difficult for ST communities to seek mental health care. Access needs to be increased by using solutions that use training of primary health workers and nonphysician health workers, task sharing, and technology-enabled clinical decision support tools.[3] The SMART Mental Health project was delivered in the tribal areas of Andhra Pradesh using those principles and was found to be beneficial by all stakeholders.[14]Given the lack of knowledge about mental health problems among these communities, the government and nongovernmental organizations should collect and disseminate data on mental disorders among the ST communities. More research funding needs to be provided and key stakeholders should be involved in creating awareness both in the community and among policy makers to develop more projects for ST communities around mental health. Two recent meetings on tribal mental health – Round Table Meeting on Mental Health of ST Populations organized by the George Institute for Global Health, India, in 2017,[51] and the First National Conference on Tribal Mental Health organized by the Indian Psychiatric Society in Bhubaneswar in 2018 – have identified some key areas of research priority for mental health in ST communities.

A national-level policy on mental health of tribal communities or population is advocated which should be developed in consultation with key stakeholders. The Indian Psychiatric Society can play a role in coordinating research activities with support of the government which can ensure regular monitoring and dissemination of the research impact to the tribal communities. There is a need to understand how mental health symptoms are perceived in different ST communities and investigate the healing practices associated with distress/disaster/death/loss/disease. This could be done in the form of cross-sectional or cohort studies to generate proper evidence which could also include the information on prevalence, mental health morbidity, and any specific patterns associated with a specific disorder. Future research should estimate the prevalence of mental disorders in different age groups and gender, risk factors, and the influence of modernization.

Studies should develop a theoretical model to understand mental disorders and promote positive mental health within ST communities. Studies should also look at different ST communities as cultural differences exist across them, and there are also differences in socioeconomic status which impact on ability to access care.Research has shown that the impact and the benefits are amplified when research is driven by priorities that are identified by indigenous communities and involve their active participation. Their knowledge and perspectives are incorporated in processes and findings. Reporting of findings is meaningful to the communities. And indigenous groups and other key stakeholders are engaged from the outset.[47] Future research in India on ST communities should also adhere to these broad principles to ensure relevant and beneficial research, which have direct impact on the mental health of the ST communities.There is also a need to update literature related to mental health of ST population continuously.

Develop culturally appropriate validated instruments to measure mental morbidity relevant to ST population. And use qualitative research to investigate the perceptions and barriers for help-seeking behavior.[48] Conclusion The current review helps not only to collate the existing literature on the mental health of ST communities but also identify gaps in knowledge and provide some indications about the type of research that should be funded in future.Financial support and sponsorshipNil.Conflicts of interestThere are no conflicts of interest. References 1.Gururaj G, Girish N, Isaac MK. Mental. Neurological and Substance abuse disorders.

Strategies towards a systems approach. In. Burden of Disease in India. Equitable development – Healthy future New Delhi, India. National Commission on Macroeconomics and Health.

Ministry of Health and Family Welfare, Government of India. 2005. 2.Math SB, Srinivasaraju R. Indian Psychiatric cipro online purchase epidemiological studies. Learning from the past.

Indian J Psychiatry 2010;52:S95-103. 3.Tewari A, Kallakuri S, Devarapalli S, Jha V, Patel A, Maulik PK. Process evaluation of the systematic medical appraisal, referral and treatment (SMART) mental health project in rural India. BMC Psychiatry 2017;17:385. 4.Ministry of Tribal Affairs, Government of India.

Report of the High Level Committee on Socio-economic, Health and Educational Status of Tribal Communities of India. New Delhi. Government of India. 2014. 5.Office of the Registrar General and Census Commissioner, Census of India.

New Delhi. Office of the Registrar General and Census Commissioner. 2011. 6.International Institute for Population Sciences and ICF. National Family Health Survey (NFHS-4), 2015-16.

India, Mumbai. International Institute for Population Sciences. 2017. 7.World Health Organization. The World Health Report 2001-Mental Health.

New Understanding, New Hope. Geneva, Switzerland. World Health Organization. 2001. 8.Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al.

Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004;291:2581-90. 9.Ministry of Health and Family Welfare, Government of India and Ministry of Tribal Affairs, Report of the Expert Committee on Tribal Health. Tribal Health in India – Bridging the Gap and a Roadmap for the Future. New Delhi.

Government of India. 2013. 10.Government of India, Rural Health Statistics 2016-17. Ministry of Health and Family Welfare Statistics Division. 2017.

11.Ormel J, VonKorff M, Ustun TB, Pini S, Korten A, Oldehinkel T. Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA 1994;272:1741-8. 12.Thornicroft G, Brohan E, Rose D, Sartorius N, Leese M, INDIGO Study Group.

Global pattern of experienced and anticipated discrimination against people with schizophrenia. A cross-sectional survey. Lancet 2009;373:408-15. 13.Armstrong G, Kermode M, Raja S, Suja S, Chandra P, Jorm AF. A mental health training program for community health workers in India.

Impact on knowledge and attitudes. Int J Ment Health Syst 2011;5:17. 14.Maulik PK, Kallakuri S, Devarapalli S, Vadlamani VS, Jha V, Patel A. Increasing use of mental health services in remote areas using mobile technology. A pre-post evaluation of the SMART Mental Health project in rural India.

J Global Health 2017;7:1-13. 15.16.Ganguly KK, Sharma HK, Krishnamachari KA. An ethnographic account of opium consumers of Rajasthan (India). Socio-medical perspective. Addiction 1995;90:9-12.

17.Chaturvedi HK, Mahanta J. Sociocultural diversity and substance use pattern in Arunachal Pradesh, India. Drug Alcohol Depend 2004;74:97-104. 18.Chaturvedi HK, Mahanta J, Bajpai RC, Pandey A. Correlates of opium use.

Retrospective analysis of a survey of tribal communities in Arunachal Pradesh, India. BMC Public Health 2013;13:325. 19.Mohindra KS, Narayana D, Anushreedha SS, Haddad S. Alcohol use and its consequences in South India. Views from a marginalised tribal population.

Drug Alcohol Depend 2011;117:70-3. 20.Sreeraj VS, Prasad S, Khess CR, Uvais NA. Reasons for substance use. A comparative study of alcohol use in tribals and non-tribals. Indian J Psychol Med 2012;34:242-6.

[PUBMED] [Full text] 21.Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders. Findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1575-86. 22.Janakiram C, Joseph J, Vasudevan S, Taha F, DeepanKumar CV, Venkitachalam R.

Prevalence and dependancy of tobacco use in an indigenous population of Kerala, India. Oral Hygiene and Health 2016;4:1 23.Manimunda SP, Benegal V, Sugunan AP, Jeemon P, Balakrishna N, Thennarusu K, et al. Tobacco use and nicotine dependency in a cross-sectional representative sample of 18,018 individuals in Andaman and Nicobar Islands, India. BMC Public Health 2012;12:515. 24.Singh PK, Singh RK, Biswas A, Rao VR.

High rate of suicide attempt and associated psychological traits in an isolated tribal population of North-East India. J Affect Dis 2013;151:673-8. 25.Sushila J. Perception of Illness and Health Care among Bhils. A Study of Udaipur District in Southern Rajasthan.

2005. 26.Sobhanjan S, Mukhopadhyay B. Perceived psychosocial stress and cardiovascular risk. Observations among the Bhutias of Sikkim, India. Stress Health 2008;24:23-34.

27.Ali A, Eqbal S. Mental Health status of tribal school going adolescents. A study from rural community of Ranchi, Jharkhand. Telangana J Psychiatry 2016;2:38-41. 28.Diwan R.

Stress and mental health of tribal and non tribal female school teachers in Jharkhand, India. Int J Sci Res Publicat 2012;2:2250-3153. 29.Longkumer I, Borooah PI. Knowledge about attitudes toward mental disorders among Nagas in North East India. IOSR J Humanities Soc Sci 2013;15:41-7.

30.Lakhan R, Kishore MT. Down syndrome in tribal population in India. A field observation. J Neurosci Rural Pract 2016;7:40-3. [PUBMED] [Full text] 31.Nizamie HS, Akhtar S, Banerjee S, Goyal N.

Health care delivery model in epilepsy to reduce treatment gap. WHO study from a rural tribal population of India. Epilepsy Res Elsevier 2009;84:146-52. 32.Prabhakar H, Manoharan R. The Tribal Health Initiative model for healthcare delivery.

A clinical and epidemiological approach. Natl Med J India 2005;18:197-204. 33.Nimgaonkar AU, Menon SD. A task shifting mental health program for an impoverished rural Indian community. Asian J Psychiatr 2015;16:41-7.

34.Yalsangi M. Evaluation of a Community Mental Health Programme in a Tribal Area- South India. Achutha Menon Centre For Health Sciences Studies, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Working Paper No 12. 2012. 35.Tripathy P, Nirmala N, Sarah B, Rajendra M, Josephine B, Shibanand R, et al.

Effect of a participatory intervention with women's groups on birth outcomes and maternal depression in Jharkhand and Orissa, India. A cluster-randomised controlled trial. Lancet 2010;375:1182-92. 36.Aparajita C, Anita KM, Arundhati R, Chetana P. Assessing Social-support network among the socio culturally disadvantaged children in India.

Early Child Develop Care 1996;121:37-47. 37.Chowdhury AN, Mondal R, Brahma A, Biswas MK. Eco-psychiatry and environmental conservation. Study from Sundarban Delta, India. Environ Health Insights 2008;2:61-76.

38.Jeffery GS, Chakrapani U. Eco-psychiatry and Environmental Conservation. Study from Sundarban Delta, India. Working Paper- Research Gate.net. September, 2016.

39.Ozer S, Acculturation, adaptation, and mental health among Ladakhi College Students a mixed methods study of an indigenous population. J Cross Cultl Psychol 2015;46:435-53. 40.Giri DK, Chaudhary S, Govinda M, Banerjee A, Mahto AK, Chakravorty PK. Utilization of psychiatric services by tribal population of Jharkhand through community outreach programme of RINPAS. Eastern J Psychiatry 2007;10:25-9.

41.Nandi DN, Banerjee G, Chowdhury AN, Banerjee T, Boral GC, Sen B. Urbanization and mental morbidity in certain tribal communities in West Bengal. Indian J Psychiatry 1992;34:334-9. [PUBMED] [Full text] 42.Hackett RJ, Sagdeo D, Creed FH. The physical and social associations of common mental disorder in a tribal population in South India.

Soc Psychiatry Psychiatr Epidemiol 2007;42:712-5. 43.Raina SK, Raina S, Chander V, Grover A, Singh S, Bhardwaj A. Development of a cognitive screening instrument for tribal elderly population of Himalayan region in northern India. J Neurosci Rural Pract 2013;4:147-53. [PUBMED] [Full text] 44.Raina SK, Raina S, Chander V, Grover A, Singh S, Bhardwaj A.

Identifying risk for dementia across populations. A study on the prevalence of dementia in tribal elderly population of Himalayan region in Northern India. Ann Indian Acad Neurol 2013;16:640-4. [PUBMED] [Full text] 45.Raina SK, Chander V, Raina S, Kumar D. Feasibility of using everyday abilities scale of India as alternative to mental state examination as a screen in two-phase survey estimating the prevalence of dementia in largely illiterate Indian population.

Indian J Psychiatry 2016;58:459-61. [PUBMED] [Full text] 46.Diwan R. Mental health of tribal male-female factory workers in Jharkhand. IJAIR 2012;2278:234-42. 47.Banerjee T, Mukherjee SP, Nandi DN, Banerjee G, Mukherjee A, Sen B, et al.

Psychiatric morbidity in an urbanized tribal (Santal) community - A field survey. Indian J Psychiatry 1986;28:243-8. [PUBMED] [Full text] 48.Leske S, Harris MG, Charlson FJ, Ferrari AJ, Baxter AJ, Logan JM, et al. Systematic review of interventions for Indigenous adults with mental and substance use disorders in Australia, Canada, New Zealand and the United States. Aust N Z J Psychiatry 2016;50:1040-54.

49.Pollock NJ, Naicker K, Loro A, Mulay S, Colman I. Global incidence of suicide among Indigenous peoples. A systematic review. BMC Med 2018;16:145. 50.Silburn K, et al.

Evaluation of the Cooperative Research Centre for Aboriginal Health (Australian institute for primary care, trans.). Melbourne. LaTrobe University. 2010. 51.

Correspondence Address:S V. Siddhardh Kumar DevarapalliGeorge Institute for Global Health, Plot No. 57, Second Floor, Corporation Bank Building, Nagarjuna Circle, Punjagutta, Hyderabad - 500 082, Telangana IndiaSource of Support. None, Conflict of Interest. NoneDOI.

10.4103/psychiatry.IndianJPsychiatry_136_19 Figures [Figure 1] Tables [Table 1], [Table 2].

What is cipro antibiotic

€‚For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts.This Focus Issue on congenital heart disease contains the Special Article ‘Transition what is cipro antibiotic to adulthood and transfer to adult care of adolescents with congenital heart disease. A global consensus statement’.1 Most children with congenital heart disease (CHD) in high-income countries survive into adulthood. Further, paediatric cardiac services have expanded in middle-income what is cipro antibiotic countries. Both evolutions have resulted in an increasing number of CHD survivors.2–5 In adolescence, patients transition from being a dependent child to an independent adult. They are also advised to transfer from paediatrics to adult what is cipro antibiotic care.

There is no universal consensus regarding how transitional care should be provided and how transfer should be organized. This consensus document describes issues and practices of transition and transfer of adolescents with CHD, accounting for different possibilities what is cipro antibiotic in high-, middle-, and low-income countries. Transitional care ought to be provided to all adolescents with CHD, taking into consideration the available resources. When reaching adulthood, patients ought to be transferred to adult care facilities/providers capable of managing their needs, and systems must be in place to make sure that continuity of high-quality care is ensured after leaving paediatric cardiology. Figure 1Suggested anticoagulation strategy for women what is cipro antibiotic with a prosthetic mechanical heart valve and (A) low-dose pre-conception vitamin K antagonist or (B) high-dose pre-conception vitamin K antagonist (from Egidy Assenza G, Dimopoulos K, Budts W, Donti A, Economy KE, Gargiulo GD, Gatzoulis M, Landzberg MJ, Valente AM, Roos-Hesselink J.

Management of acute cardiovascular complications in pregnancy. See pages 4224–4240).Figure 1Suggested anticoagulation strategy for women with a prosthetic mechanical heart valve and (A) low-dose pre-conception vitamin K antagonist or (B) high-dose pre-conception vitamin K antagonist (from Egidy Assenza G, Dimopoulos what is cipro antibiotic K, Budts W, Donti A, Economy KE, Gargiulo GD, Gatzoulis M, Landzberg MJ, Valente AM, Roos-Hesselink J. Management of acute cardiovascular complications in pregnancy. See pages 4224–4240).In a State of the Art Review article entitled ‘Management of acute cardiovascular complications in pregnancy’, Gabriele Egidy Assenza from the IRCCS Azienda Ospedaliero-Universitaria di Bologna in Italy and colleagues note that the growing population of women of reproductive age with heart disease has been associated with an increasing number of high-risk pregnancies.6 Pregnant women with heart disease are a very heterogeneous population, with different risks for maternal cardiovascular, obstetric, and foetal complications.7–11 Adverse cardiovascular events during pregnancy pose significant clinical what is cipro antibiotic challenges, with uncertainties regarding diagnostic and therapeutic approaches potentially compromising maternal and foetal health. This review provides a summary of recommendations on the management of acute cardiovascular complications during pregnancy, based on available literature and expert opinion.

The authors cover the diagnosis, risk stratification, and therapy, and the review is organized according to the clinical presentation and the type of complication, providing a reference for the practising cardiologist, obstetrician, and acute medicine specialist, while highlighting areas of need and potential future research. Topics covered include what is cipro antibiotic heart failure (HF), arrhythmias, coronary artery disease, aortic and thrombo-embolic events, and the management of mechanical heart valves during pregnancy (Figure 1). Figure 2Graphical Abstract (from Diller GP, Orwat S, Lammers AE, Radke RM, De-Torres-Alba F, Schmidt R, Marschall U, Bauer UM, Enders D, Bronstein L, Kaleschke G, Baumgartner H. Lack of specialist care is associated with increased morbidity and mortality what is cipro antibiotic in adult congenital heart disease. A population-based study.

See pages 4241–4248).Figure 2Graphical Abstract (from Diller GP, Orwat S, Lammers AE, Radke what is cipro antibiotic RM, De-Torres-Alba F, Schmidt R, Marschall U, Bauer UM, Enders D, Bronstein L, Kaleschke G, Baumgartner H. Lack of specialist care is associated with increased morbidity and mortality in adult congenital heart disease. A population-based what is cipro antibiotic study. See pages 4241–4248).In a Clinical Research article entitled ‘Lack of specialist care is associated with increased morbidity and mortality in adult congenital heart disease. A population-based study’, Gerhard-Paul Diller from the University Hospital Münster in Germany, and colleagues aimed to provide population-based data on the healthcare provision for adults with congenital heart disease (ACHD) and the impact of cardiology care on morbidity and mortality in this vulnerable population.12 Based on administrative data from one of the largest German Health Insurance Companies, all insured ACHD patients (<70 years of age) were included.

Patients were stratified into those followed exclusively by primary care what is cipro antibiotic physicians (PCPs) and those with additional cardiology follow-up between 2014 and 2016. Associations between level of care and outcome were assessed by multivariable/propensity score Cox analyses. Overall, 24 139 patients (median age 43 years, 54.8% female) were included what is cipro antibiotic. Of these, only 50% had cardiology follow-up during the 3-year period, with 49% of patients only being cared for by PCPs and 1% having no contact with either. After comprehensive multivariable and propensity score adjustment, ACHD patients under cardiology follow-up had what is cipro antibiotic a significantly lower risk of death [hazard ratio (HR) 0.81.

P = 0.03] or major events (HR 0.85. P < 0.001) compared with those only followed by PCPs. At 3-year follow-up, the absolute risk difference for mortality was what is cipro antibiotic 0.9% higher in ACHD patients with moderate/severe complexity lesions under the care of PCPs compared with those under cardiology follow-up (Figure 2). The authors conclude that cardiology care compared with primary care is associated with superior survival and lower rates of major complications in ACHD. It is alarming that even in what is cipro antibiotic a high-resource setting with well-established specialist ACHD care, ∼50% of contemporary ACHD patients are still not linked to regular cardiac care.

Thus, more efforts are required to alert PCPs and patients to appropriate ACHD care. The manuscript is accompanied by an Editorial by Anne Marie Valente from the Brigham and Women’s Hospital in Boston, MA, USA and what is cipro antibiotic Abigail Khan from the Oregon Health and Science University in Portland, OR, USA.13 The authors conclude that it is clear that cardiology care matters for adults living with CHD. The next step for us all is to take this message forward, educating providers, empowering patients, and developing better care networks to support this growing population of individuals with complex care needs.In a Clinical Research article entitled ‘Maternal and neonatal complications in women with congenital heart disease. A nationwide analysis’, Astrid Elisabeth Lammers from the University Hospital Münster in Germany, and colleagues provide population-based data on maternal and neonatal complications and outcome in pregnancies of women with congenital heart disease (CHD).14 Based on what is cipro antibiotic administrative data from one of the largest German Health Insurance Companies (BARMER GEK, ∼9 million members representative for Germany), all pregnancies in women with CHD between 2005 and 2018 were analysed. In addition, an age-matched non-CHD control group was included for comparison, and the association between ACHD and maternal or neonatal outcomes was investigated.

Overall, 7512 pregnancies occurred in 4015 women with CHD. The matched non-CHD control group included 6502 women what is cipro antibiotic with 11 225 pregnancies. Caesarean deliveries were more common in CHD patients (40.5% vs. 31.5% in the control group what is cipro antibiotic. P <.

0.001). There was no excess mortality. Although the maternal complication rate was low in absolute terms, women with CHD had a significantly higher rate of stroke, HF, and cardiac arrhythmias during pregnancy (P <0.001 for all). Neonatal mortality was low but also significantly higher in the ACHD group (0.83% vs. 0.22%.

P = 0.001), and neonates to CHD mothers had significantly low/extremely low birth weight or extreme immaturity, or required resuscitation and mechanical ventilation more often compared with non-CHD offspring. On multivariate logistic regression, maternal defect complexity, arterial hypertension, HF, prior fertility treatment, and anticoagulation with vitamin K antagonists emerged as significant predictors of adverse neonatal outcome. Recurrence of CHD was 6.1 times higher in infants to ACHD mothers compared with controls.The authors conclude that this population-based study illustrates a reassuringly low maternal mortality rate in a highly developed healthcare system. Nevertheless, maternal morbidity and neonatal morbidity/mortality were significantly increased in women with ACHD, highlighting the need for specialized care and pre-pregnancy counselling. This manuscript is accompanied by an Editorial by Jolien W.

Roos-Hesselink from Erasmus MC in Rotterdam, the Netherlands, and colleagues.15 The authors note that the study by Lammers et al. Is an excellent and clinically relevant contribution to the existing literature on pregnancy in women with CHD. The study shows that a good healthcare system, a multidisciplinary approach, and decisive pre-pregnancy counselling are effective in achieving safe pregnancies. Pre-pregnancy counselling with an individualized approach is a crucial step in this process, because both maternal and perinatal outcomes vary largely by the complexity of maternal illness, and further studies dedicated to specific congenital diagnoses are still warranted.Left ventricular non-compaction (LVNC) cardiomyopathy is a devastating genetic disease caused by insufficient consolidation of ventricular wall muscle that can result in inadequate cardiac performance.16 Despite being the third most common cardiomyopathy, the mechanisms underlying the disease, including the cell types involved, are poorly understood. In a Translational Research article entitled ‘Endocardial/endothelial angiocrines regulate cardiomyocyte development and maturation and induce features of ventricular non-compaction’, Siyeon Rhee from Stanford University in Stanford, CA, USA, and colleagues aimed to identify candidate angiocrines expressed by endocardial and endothelial cells in embryonic hearts of Tie2Cre;Ino80fl/fl transgenic mouse (an experimental model of LVNC).

Then they tested the effect of these candidates on cardiomyocyte proliferation and maturation.17 The authors observed a pathological endocardial cell population in non-compacted hearts and identified multiple dysregulated angiocrine factors that dramatically affected cardiomyocyte behaviour. They identified Col15a1 as a coronary vessel-secreted angiocrine factor, down-regulated by Ino80 deficiency, that functioned to promote cardiomyocyte proliferation. Furthermore, mutant endocardial and endothelial cells up-regulated expression of secreted factors, such as Tgfbi, Igfbp3, Isg15, and Adm, which decreased cardiomyocyte proliferation.The authors conclude that these findings support a model where coronary endothelial cells normally promote myocardial compaction through secreted factors, but that endocardial and endothelial cells can secrete factors that contribute to non-compaction under pathological conditions. The contribution is accompanied by an Editorial by Stefanie Dimmeler and Julian Wagner from the Goethe University in Frankfurt, Germany.18 The authors note that the study by Rhee et al. Elegantly identifies the importance of a timely orchestrated and well-balanced repertoire of extracellular factors that coordinate the proper development of the left ventricle.

It will be important to learn more about the cellular cross-talk to understand the mechanisms of cardiac development and homeostasis. The interplay between endothelial cells and other vascular cells such as pericytes and smooth muscle cells, and fibroblasts and immune cells, with cardiomyocytes has to be taken into account. The modulation of extracellular matrix proteins and paracrine factors may also be a therapeutic strategy promoting cardiac repair and regeneration, but probably needs to be carefully adapted to the underlying stage and type of heart disease.The issue is also complemented by two Discussion Forum contributions. In a commentary entitled ‘Big cohort studies offer insights into preventable risk factors’, Karolina Agnieszka Wartolowska and Alastair John Stewart Webb from the John Radcliffe Hospital in Oxford, UK comment on the recent Editorial ‘On cerebrotoxicity of antihypertensive therapy and risk factor cosmetics’ by Franz H. Messerli from the University of Bern in Switzerland.19,20 Messerli et al.

Respond in a separate comment.21The editors hope that this issue of the European Heart Journal will be of interest to its readers.With thanks to Amelia Meier-Batschelet, Johanna Huggler, and Martin Meyer for help with compilation of this article. References1Moons P, Bratt EL, De Backer J, Goossens E, Hornung T, Tutarel O, Zühlke L, Araujo JJ, Callus E, Gabriel H, Shahid N, Sliwa K, Verstappen A, Yang HL, Thomet C. Transition to adulthood and transfer to adult care of adolescents with congenital heart disease. A global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (ACNAP), the ESC Working Group on Adult Congenital Heart Disease (WG ACHD), the Association for European Paediatric and Congenital Cardiology (AEPC), the Pan-African Society of Cardiology (PASCAR), the Asia-Pacific Pediatric Cardiac Society (APPCS), the Inter-American Society of Cardiology (IASC), the Cardiac Society of Australia and New Zealand (CSANZ), the International Society for Adult Congenital Heart Disease (ISACHD), the World Heart Federation (WHF), the European Congenital Heart Disease Organisation (ECHDO), and the Global Alliance for Rheumatic and Congenital Hearts (Global ARCH). Eur Heart J 2021;42:4213–4223.2Chessa M, Brida M, Gatzoulis MA, Diller GP, Roos-Hesselink JW, Dimopoulos K, Behringer W, Möckel M, Giamberti A, Galletti L, Price S, Baumgartner H, Gallego P, Tutarel O.

Emergency department management of patients with adult congenital heart disease. A consensus paper from the ESC Working Group on Adult Congenital Heart Disease, the European Society for Emergency Medicine (EUSEM), the European Association for Cardio-Thoracic Surgery (EACTS), and the Association for Acute Cardiovascular Care (ACVC). Eur Heart J 2021;42:2527–2535.3Diller GP, Gatzoulis MA, Broberg CS, Aboulhosn J, Brida M, Schwerzmann M, Chessa M, Kovacs AH, Roos-Hesselink J. antibiotics disease 2019 in adults with congenital heart disease. A position paper from the ESC working group of adult congenital heart disease, and the International Society for Adult Congenital Heart Disease.

Eur Heart J 2021;42:1858–1865.4Diller GP, Lammers AE, Enders D, Baumgartner H. Maternal and neonatal complications in women with congenital heart disease. Results from a nationwide analysis including 7,231 pregnancies. Eur Heart J 2020;41(Suppl_2). Doi:10.1093/eurheartj/ehaa946.2215.5Playan Escribano J, Segura De La Cal T, Segovia Cubero J, Rueda Soriano J, Garcia Hernandez FJ, Lopez Meseguer M, Perez Penate GM, Lara Padron A, Campo Ezquibela A, Sala Llinas E, Mombiela T, Guerra Ramos FJ, Samper GJ, Blanco I, Escribano Subias P, REHAP Investigators.

Pulmonary hypertension and congenital heart disease. Medical treatment and risk factors for survival. Eur Heart J 2020;41(Suppl_2). Doi:10.1093/eurheartj/ehaa946.2299.6Egidy Assenza G, Dimopoulos K, Budts W, Donti A, Economy KE, Gargiulo GD, Gatzoulis M, Landzberg MJ, Valente AM, Roos-Hesselink J. Management of acute cardiovascular complications in pregnancy.

Eur Heart J 2021;42:4224–4240.7Maas A, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, Kunadian V, Laan E, Lambrinoudaki I, Maclaran K, Panay N, Stevenson JC, van Trotsenburg M, Collins P. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions. A consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J 2021;42:967–984.8Al-Hussaini A. Pregnancy and aortic dissections.

Eur Heart J 2020;41:4243–4244.9Beyer SE, Dicks AB, Shainker SA, Feinberg L, Schermerhorn ML, Secemsky EA, Carroll BJ. Pregnancy-associated arterial dissections. A nationwide cohort study. Eur Heart J 2020;41:4234–4242.10Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, Jondeau G, Budts W, Grewal J, Sliwa K, Parsonage W, Maggioni AP, van Hagen I, Vahanian A, Tavazzi L, Elkayam U, Boersma E, Hall R. Pregnancy outcomes in women with cardiovascular disease.

Evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J 2019;40:3848–3855.11Koenig T, Hilfiker-Kleiner D. Future cardiovascular risk prediction in women with pregnancy complications. The HUNT is on. Eur Heart J 2019;40:1121–1123.12Diller GP, Orwat S, Lammers AE, Radke RM, De-Torres-Alba F, Schmidt R, Marschall U, Bauer UM, Enders D, Bronstein L, Kaleschke G, Baumgartner H.

Lack of specialist care is associated with increased morbidity and mortality in adult congenital heart disease. A population-based study. Eur Heart J 2021;42:4241–4248.13Khan AD, Valente AM. Don’t be alarmed. The need for enhanced partnerships between medical communities to improve outcomes for adults living with congenital heart disease.

Eur Heart J 2021;42:4249–4251.14Lammers AE, Diller G-P, Lober R, Möllers M, Schmidt R, Radke RM, De-Torres-Alba F, Kaleschke G, Marschall U, Bauer UM, Gerß J, Enders D, Baumgartner H. Maternal and neonatal complications in women with congenital heart disease. A nationwide analysis. Eur Heart J 2021;42:4252–4260.15Ramlakhan KP, Roos-Hesselink JW. Promising perspectives on pregnancy in women with congenital heart disease.

Eur Heart J 2021;42:4261–4263.16Ross SB, Jones K, Blanch B, Puranik R, McGeechan K, Barratt A, Semsarian C. A systematic review and meta-analysis of the prevalence of left ventricular non-compaction in adults. Eur Heart J 2020;41:1428–1436.17Rhee S, Paik DT, Yang JY, Nagelberg D, Williams I, Tian L, Roth R, Chandy M, Ban J, Belbachir N, Kim S, Zhang H, Phansalkar R, Wong KM, King DA, Valdez C, Winn VD, Morrison AJ, Wu JC, Red-Horse K. Endocardial/endothelial angiocrines regulate cardiomyocyte development and maturation and induce features of ventricular non-compaction. Eur Heart J 2021;42:4264–4276.18Wagner JUG, Dimmeler S.

The endothelial niche in heart failure. From development to regeneration. Eur Heart J 2021;42:4277–4279.19Wartolowska KA, Webb AJS. Big cohort studies offer insights into preventable risk factors. Eur Heart J 2021;42:4280–4281.20Huang HK, Liu PP, Hsu JY, Lin SM, Peng CC, Wang JH, Loh CH.

Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants. A real-world nationwide cohort study. Eur Heart J 2020;41:1100–1108.21Messerli FH, Bavishi C, Messerli AW, Siontis GCM. Cerebrotoxicity of antihypertensive therapy in the UK Biobank Cohort Study. Eur Heart J 2021;42:4282.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email. Journals.permissions@oup.com.This editorial refers to ‘Maternal and neonatal complications in women with congenital heart disease.

A nationwide analysis’, by A.E. Lammers et al., https://doi.org/10.1093/eurheartj/ehab571.With the increasing survival of children born with congenital heart disease into adult age, the focus has shifted from survival to quality of life. Most patients wish to live a normal life, including participation in sports and also starting a family. In earlier times, concerns were raised about the risks of pregnancy, as pregnancy is associated with impressive hormonal changes and haemodynamic impact. Older studies reported high rates of maternal complications, including maternal mortality, and substantial rates of perinatal complications.1–3 In addition, there were concerns about the hereditable recurrence risk of congenital heart disease for the baby.

However, studies were limited by small sample size or retrospective study design, and for a long time only the reported data from Nora and Nora were available.4 As a result, many physicians and, thus patients, were reluctant to embark on pregnancy, especially in more complex congenital heart disease, such as women with a systemic right ventricle, but also in severe aortic stenosis. The risks were deemed very high or too high, and these women were typically advised against pregnancy. Although research in the field of pregnancy and congenital heart disease is hampered by small numbers, often with retrospective design, over the past decades gradually some larger studies and registries became available, elucidating the risks of pregnancy and in fact showing relatively good results. A clear development over time in adult patients with congenital heart disease (ACHD) was seen for instance in women with transposition of the great arteries corrected with the Mustard and Senning operation, which started as being seen as very high risk, to high risk, and now to moderate risk. The trend for women with aortic stenosis is now also to allow pregnancy, even when the stenosis is severe, as long as the woman is asymptomatic.5–7The study of Lammers et al.

In this issue of the European Heart Journal provides an important contribution to the existing literature.8 Not only is this the largest study, but it includes all women with ACHD, without a possible bias of only including patients seen at a tertiary centre or including patients with other kinds of heart disease. Furthermore, because it is performed in a western country with an optimal healthcare system, the results are applicable to other western countries with comparable systems of care organization with appropriate counselling in place and good collaboration between cardiac and obstetric care. The pregnancy outcomes in studies with a global perspective, including patients from developing countries, show less favourable results (Graphical Abstract).8,9 These differences illustrate how the healthcare system and environment of women have great impact on their pregnancy outcomes and show that we still need to work to improve these outcomes for all women worldwide.10 A possible step forward is to utilize the expertise in the specialized healthcare centres such as described by Lammers et al., by providing long-distance digital or telephone consultations to rural centres in developing countries. Lammers et al. Also describe better pregnancy outcomes than an older study (1980–2007) in a Dutch and Belgian healthcare system similar to the German system, which may be due to advances in medical care for both the treatment of the original heart defect in the mother, and the management of pregnancy in heart disease, which includes the introduction of multidisciplinary pregnancy heart teams and the establishment of international guidelines (Graphical Abstract).8,11 Graphical AbstractComparison of studies on pregnancy outcomes of women with congenital heart disease.

ACHD. Adult congenital heart disease.Graphical AbstractComparison of studies on pregnancy outcomes of women with congenital heart disease. ACHD. Adult congenital heart disease.The most important finding of this well-performed and excellently written study is the zero maternal mortality in women with congenital heart disease.8 This is unexpected and fantastic news. As the authors point out, this is partly the result of good counselling, where the high-risk patients were advised against pregnancy and most probably did not become pregnant.

However, other studies show that some women at highest risk (mWHO IV) will actually still become pregnant, irrespective of counselling. In any case, this important finding makes it possible to reassure the large majority of ACHD patients about the mortality risk of pregnancy. This is an important message and should lead to a change in policy from approaching pregnancy as potentially very dangerous, to considering pregnancy as relatively safe and explaining the possible risks, on the condition that women in mWHO IV should not become pregnant. Of course morbidity is increased, but the rates are relatively low. The prevalence of heart failure in pregnancy might be under-reported in the study of Lammers et al., because pregnancies in women who had heart failure in the year before the pregnancy were not considered to be complicated by heart failure, probably because of the limitations of the method of registration with ICD codes.

The relationship between the occurrence of stroke and having a co-existent atrial septal defect or patent foramen ovale is shown nicely and should lead to a more proactive approach in taking lifestyle measures and considering a low threshold to prescribing antiplatelet drugs in these women. As in other studies, the mode of delivery is more often by Caesarean section in women with congenital heart disease, while this is not advised in the latest guidelines.6 An attempt must be made to change this policy, because planned Caesarean section in women with heart disease does not improve maternal outcome over vaginal delivery and can be harmful for neonatal outcome.12Another important finding of this study is the relatively high risk of the baby also having congenital heart disease.8 This study provides data on the numbers of children needing cardiac surgery with the use of cardiopulmonary bypass at young age, as a nice surrogate marker for congenital heart disease needing treatment, and reports 6% in ACHD patients vs. 0.4% in the general population. Scarce data were available on this topic, and for many years we had to rely on old studies.4 In particular, the comparison with the age-matched control group in this study provides the opportunity to finally gain reliable estimates. In counselling we can now inform our patients that the risk for their baby to also have congenital heart disease requiring surgery within ≤6 years is ∼15 times higher, compared with the general population (6% vs.

0.4%).8 What is astonishing is the reported rate for a univentricular heart being as high as 26.5%. Until now there was no reliable information on this specific congenital defect, because most women did not have children. However, this high rate fuels the discussion on pregnancy for women after Fontan correction. In addition to the high rates of miscarriage and maternal and foetal complications and the fear of the long-term impact on the maternal condition, now the high rate of foetal congenital defects also has to be taken into account when deciding on pregnancy in these high-risk women. It would be of interest to study trends over time, as earlier and better prenatal diagnostics and changes in termination management might have an impact, not only in these complex defects but also in less complex cardiac defects.In conclusion, the study by Lammers et al.

Is an excellent and clinically relevant contribution to the existing literature on pregnancy in women with congenital heart disease. The study shows that a good healthcare system, a multidisciplinary approach, and decisive pre-pregnancy counselling are effective in achieving safe pregnancies. Pre-pregnancy counselling with an individualized approach is a crucial step in this process, because both maternal and perinatal outcomes vary greatly by the complexity of maternal illness, and further studies dedicated to specific congenital diagnoses remain warranted.Conflict of interest. None declared.The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. References1Mendelson CL.

Pregnancy and coarctation of the aorta. Am J Obstet Gynecol 1940;39:1014–1021.2Arias F, Pineda J. Aortic stenosis and pregnancy. J Reprod Med 1978;20:229–232.3Presbitero P, Somerville J, Stone S, Aruta E, Spiegelhalter D, Rabajoli F. Pregnancy in cyanotic congenital heart disease.

Outcome of mother and fetus. Circulation 1994;89:2673–2676.4Nora JJ, Nora AH. Recurrence risks in children having one parent with a congenital heart disease. Circulation 1976;53:701–702.5Orwat S, Diller GP, van Hagen IM, Schmidt R, Tobler D, Greutmann M, Jonkaitiene R, Elnagar A, Johnson MR, Hall R, Roos-Hesselink JW, Baumgartner H. ROPAC Investigators.

Risk of pregnancy in moderate and severe aortic stenosis. From the multinational ROPAC registry. J Am Coll Cardiol 2016;68:1727–1737.6Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T, Swan L, Warnes CA. ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.

Eur Heart J 2018;39:3165–241.7Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, Jondeau G, Budts W, Grewal J, Sliwa K, Parsonage W, Maggioni AP, van Hagen I, Vahanian A, Tavazzi L, Elkayam U, Boersma E, Hall R. Pregnancy outcomes in women with cardiovascular disease. Evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J 2019;40:1–8.8Lammers AE, Diller GP, Lober R, Möllers M, Schmidt R, Radke RM, De-Torres-Alba F, Kaleschke G, Marschall U, Bauer UM, Gerβ J, Enders D, Baumgartner H. Maternal and neonatal complications in women with congenital heart disease.

A nationwide analysis. Eur Heart J 2021;42:4252–4260.9Ramlakhan KP, Johnson MR, Lelonek M, Saadd A, Gasimove Z, Sharashkinaf NV, Thorntong P, Arstallh M, Halli R, Roos-Hesselinka JW, on behalf of the ROPAC Investigators Group, ROPAC Executive Committee, ROPAC Investigators. Congenital heart disease in the ESC EORP Registry of Pregnancy and Cardiac disease (ROPAC). Int J Cardiol Congenital Heart Dis 2021;3:100107.10Independent Group of Scientists appointed by the Secretary-General. Global Sustainable Development Report 2019.

The Future is Now. Science for Achieving Sustainable Development. New York. 2019.11Drenthen W, Boersma E, Balci A, Moons P, Roos-Hesselink JW, Mulder BJ, Vliegen HW, van Dijk AP, Voors AA, Yap SC, van Veldhuisen DJ, Pieper PG. ZAHARA Investigators.

Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010;31:2124–2132.12Ruys TP, Roos-Hesselink JW, Pijuan-Domenech A, Vasario E, Gaisin IR, Iung B, Freeman LJ, Gordon EP, Pieper PG, Hall R, Boersma E, Johnson MR. ROPAC investigators. Is a planned caesarean section in women with cardiac disease beneficial?. Heart 2015;101:530–536.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email. Journals.permissions@oup.com..

€‚For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts.This Focus Issue what i should buy with cipro on congenital heart disease contains the Special Article ‘Transition to adulthood and transfer to adult care of adolescents with congenital heart disease. A global consensus statement’.1 Most children with congenital heart disease (CHD) in high-income countries survive into adulthood. Further, paediatric cardiac services have what i should buy with cipro expanded in middle-income countries. Both evolutions have resulted in an increasing number of CHD survivors.2–5 In adolescence, patients transition from being a dependent child to an independent adult. They are also what i should buy with cipro advised to transfer from paediatrics to adult care.

There is no universal consensus regarding how transitional care should be provided and how transfer should be organized. This consensus document describes issues and practices of transition and transfer of adolescents with CHD, accounting for different possibilities what i should buy with cipro in high-, middle-, and low-income countries. Transitional care ought to be provided to all adolescents with CHD, taking into consideration the available resources. When reaching adulthood, patients ought to be transferred to adult care facilities/providers capable of managing their needs, and systems must be in place to make sure that continuity of high-quality care is ensured after leaving paediatric cardiology. Figure 1Suggested anticoagulation strategy for women with a prosthetic mechanical heart valve and (A) low-dose pre-conception vitamin K antagonist or (B) high-dose pre-conception vitamin K antagonist (from Egidy Assenza G, Dimopoulos K, Budts W, Donti what i should buy with cipro A, Economy KE, Gargiulo GD, Gatzoulis M, Landzberg MJ, Valente AM, Roos-Hesselink J.

Management of acute cardiovascular complications in pregnancy. See pages 4224–4240).Figure 1Suggested anticoagulation strategy for women with a what i should buy with cipro prosthetic mechanical heart valve and (A) low-dose pre-conception vitamin K antagonist or (B) high-dose pre-conception vitamin K antagonist (from Egidy Assenza G, Dimopoulos K, Budts W, Donti A, Economy KE, Gargiulo GD, Gatzoulis M, Landzberg MJ, Valente AM, Roos-Hesselink J. Management of acute cardiovascular complications in pregnancy. See pages 4224–4240).In a State of the Art Review article entitled ‘Management of acute cardiovascular complications in pregnancy’, Gabriele Egidy Assenza from the IRCCS Azienda Ospedaliero-Universitaria di Bologna in Italy and colleagues note that the growing population of women of reproductive age with heart disease has been associated with an what i should buy with cipro increasing number of high-risk pregnancies.6 Pregnant women with heart disease are a very heterogeneous population, with different risks for maternal cardiovascular, obstetric, and foetal complications.7–11 Adverse cardiovascular events during pregnancy pose significant clinical challenges, with uncertainties regarding diagnostic and therapeutic approaches potentially compromising maternal and foetal health. This review provides a summary of recommendations on the management of acute cardiovascular complications during pregnancy, based on available literature and expert opinion.

The authors cover the diagnosis, risk stratification, and therapy, and the review is organized according to the clinical presentation and the type of complication, providing a reference for the practising cardiologist, obstetrician, and acute medicine specialist, while highlighting areas of need and potential future research. Topics covered what i should buy with cipro include heart failure (HF), arrhythmias, coronary artery disease, aortic and thrombo-embolic events, and the management of mechanical heart valves during pregnancy (Figure 1). Figure 2Graphical Abstract (from Diller GP, Orwat S, Lammers AE, Radke RM, De-Torres-Alba F, Schmidt R, Marschall U, Bauer UM, Enders D, Bronstein L, Kaleschke G, Baumgartner H. Lack of specialist care what i should buy with cipro is associated with increased morbidity and mortality in adult congenital heart disease. A population-based study.

See pages 4241–4248).Figure 2Graphical Abstract (from Diller GP, Orwat S, Lammers AE, Radke RM, De-Torres-Alba F, Schmidt R, Marschall U, Bauer UM, Enders D, Bronstein L, Kaleschke what i should buy with cipro G, Baumgartner H. Lack of specialist care is associated with increased morbidity and mortality in adult congenital heart disease. A population-based what i should buy with cipro study. See pages 4241–4248).In a Clinical Research article entitled ‘Lack of specialist care is associated with increased morbidity and mortality in adult congenital heart disease. A population-based study’, Gerhard-Paul Diller from the University Hospital Münster in Germany, and colleagues aimed to provide population-based data on the healthcare provision for adults with congenital heart disease (ACHD) and the impact of cardiology care on morbidity and mortality in this vulnerable population.12 Based on administrative data from one of the largest German Health Insurance Companies, all insured ACHD patients (<70 years of age) were included.

Patients were stratified into those followed exclusively what i should buy with cipro by primary care physicians (PCPs) and those with additional cardiology follow-up between 2014 and 2016. Associations between level of care and outcome were assessed by multivariable/propensity score Cox analyses. Overall, 24 what i should buy with cipro 139 patients (median age 43 years, 54.8% female) were included. Of these, only 50% had cardiology follow-up during the 3-year period, with 49% of patients only being cared for by PCPs and 1% having no contact with either. After comprehensive multivariable and propensity score adjustment, ACHD patients under cardiology follow-up had a significantly lower risk of death [hazard ratio what i should buy with cipro (HR) 0.81.

P = 0.03] or major events (HR 0.85. P < 0.001) compared with those only followed by PCPs. At 3-year follow-up, the absolute risk what i should buy with cipro difference for mortality was 0.9% higher in ACHD patients with moderate/severe complexity lesions under the care of PCPs compared with those under cardiology follow-up (Figure 2). The authors conclude that cardiology care compared with primary care is associated with superior survival and lower rates of major complications in ACHD. It is alarming that even in a high-resource setting with well-established specialist ACHD care, ∼50% of contemporary ACHD patients what i should buy with cipro are still not linked to regular cardiac care.

Thus, more efforts are required to alert PCPs and patients to appropriate ACHD care. The manuscript is accompanied by an Editorial by Anne Marie Valente from the Brigham and Women’s Hospital in Boston, MA, USA and Abigail Khan from the Oregon Health and Science University in Portland, OR, USA.13 The authors conclude that it is clear that cardiology care matters for adults living with what i should buy with cipro CHD. The next step for us all is to take this message forward, educating providers, empowering patients, and developing better care networks to support this growing population of individuals with complex care needs.In a Clinical Research article entitled ‘Maternal and neonatal complications in women with congenital heart disease. A nationwide analysis’, Astrid Elisabeth Lammers from the University Hospital Münster in Germany, and colleagues provide population-based data on maternal and neonatal complications and outcome in pregnancies of women with congenital heart disease (CHD).14 Based on administrative data from one of the largest German Health Insurance what i should buy with cipro Companies (BARMER GEK, ∼9 million members representative for Germany), all pregnancies in women with CHD between 2005 and 2018 were analysed. In addition, an age-matched non-CHD control group was included for comparison, and the association between ACHD and maternal or neonatal outcomes was investigated.

Overall, 7512 pregnancies occurred in 4015 women with CHD. The matched non-CHD control group included 6502 women with 11 225 pregnancies what i should buy with cipro. Caesarean deliveries were more common in CHD patients (40.5% vs. 31.5% in what i should buy with cipro the control group. P <.

0.001). There was no excess mortality. Although the maternal complication rate was low in absolute terms, women with CHD had a significantly higher rate of stroke, HF, and cardiac arrhythmias during pregnancy (P <0.001 for all). Neonatal mortality was low but also significantly higher in the ACHD group (0.83% vs. 0.22%.

P = 0.001), and neonates to CHD mothers had significantly low/extremely low birth weight or extreme immaturity, or required resuscitation and mechanical ventilation more often compared with non-CHD offspring. On multivariate logistic regression, maternal defect complexity, arterial hypertension, HF, prior fertility treatment, and anticoagulation with vitamin K antagonists emerged as significant predictors of adverse neonatal outcome. Recurrence of CHD was 6.1 times higher in infants to ACHD mothers compared with controls.The authors conclude that this population-based study illustrates a reassuringly low maternal mortality rate in a highly developed healthcare system. Nevertheless, maternal morbidity and neonatal morbidity/mortality were significantly increased in women with ACHD, highlighting the need for specialized care and pre-pregnancy counselling. This manuscript is accompanied by an Editorial by Jolien W.

Roos-Hesselink from Erasmus MC in Rotterdam, the Netherlands, and colleagues.15 The authors note that the study by Lammers et al. Is an excellent and clinically relevant contribution to the existing literature on pregnancy in women with CHD. The study shows that a good healthcare system, a multidisciplinary approach, and decisive pre-pregnancy counselling are effective in achieving safe pregnancies. Pre-pregnancy counselling with an individualized approach is a crucial step in this process, because both maternal and perinatal outcomes vary largely by the complexity of maternal illness, and further studies dedicated to specific congenital diagnoses are still warranted.Left ventricular non-compaction (LVNC) cardiomyopathy is a devastating genetic disease caused by insufficient consolidation of ventricular wall muscle that can result in inadequate cardiac performance.16 Despite being the third most common cardiomyopathy, the mechanisms underlying the disease, including the cell types involved, are poorly understood. In a Translational Research article entitled ‘Endocardial/endothelial angiocrines regulate cardiomyocyte development and maturation and induce features of ventricular non-compaction’, Siyeon Rhee from Stanford University in Stanford, CA, USA, and colleagues aimed to identify candidate angiocrines expressed by endocardial and endothelial cells in embryonic hearts of Tie2Cre;Ino80fl/fl transgenic mouse (an experimental model of LVNC).

Then they tested the effect of these candidates on cardiomyocyte proliferation and maturation.17 The authors observed a pathological endocardial cell population in non-compacted hearts and identified multiple dysregulated angiocrine factors that dramatically affected cardiomyocyte behaviour. They identified Col15a1 as a coronary vessel-secreted angiocrine factor, down-regulated by Ino80 deficiency, that functioned to promote cardiomyocyte proliferation. Furthermore, mutant endocardial and endothelial cells up-regulated expression of secreted factors, such as Tgfbi, Igfbp3, Isg15, and Adm, which decreased cardiomyocyte proliferation.The authors conclude that these findings support a model where coronary endothelial cells normally promote myocardial compaction through secreted factors, but that endocardial and endothelial cells can secrete factors that contribute to non-compaction under pathological conditions. The contribution is accompanied by an Editorial by Stefanie Dimmeler and Julian Wagner from the Goethe University in Frankfurt, Germany.18 The authors note that the study by Rhee et al. Elegantly identifies the importance of a timely orchestrated and well-balanced repertoire of extracellular factors that coordinate the proper development of the left ventricle.

It will be important to learn more about the cellular cross-talk to understand the mechanisms of cardiac development and homeostasis. The interplay between endothelial cells and other vascular cells such as pericytes and smooth muscle cells, and fibroblasts and immune cells, with cardiomyocytes has to be taken into account. The modulation of extracellular matrix proteins and paracrine factors may also be a therapeutic strategy promoting cardiac repair and regeneration, but probably needs to be carefully adapted to the underlying stage and type of heart disease.The issue is also complemented by two Discussion Forum contributions. In a commentary entitled ‘Big cohort studies offer insights into preventable risk factors’, Karolina Agnieszka Wartolowska and Alastair John Stewart Webb from the John Radcliffe Hospital in Oxford, UK comment on the recent Editorial ‘On cerebrotoxicity of antihypertensive therapy and risk factor cosmetics’ by Franz H. Messerli from the University of Bern in Switzerland.19,20 Messerli et al.

Respond in a separate comment.21The editors hope that this issue of the European Heart Journal will be of interest to its readers.With thanks to Amelia Meier-Batschelet, Johanna Huggler, and Martin Meyer for help with compilation of this article. References1Moons P, Bratt EL, De Backer J, Goossens E, Hornung T, Tutarel O, Zühlke L, Araujo JJ, Callus E, Gabriel H, Shahid N, Sliwa K, Verstappen A, Yang HL, Thomet C. Transition to adulthood and transfer to adult care of adolescents with congenital heart disease. A global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (ACNAP), the ESC Working Group on Adult Congenital Heart Disease (WG ACHD), the Association for European Paediatric and Congenital Cardiology (AEPC), the Pan-African Society of Cardiology (PASCAR), the Asia-Pacific Pediatric Cardiac Society (APPCS), the Inter-American Society of Cardiology (IASC), the Cardiac Society of Australia and New Zealand (CSANZ), the International Society for Adult Congenital Heart Disease (ISACHD), the World Heart Federation (WHF), the European Congenital Heart Disease Organisation (ECHDO), and the Global Alliance for Rheumatic and Congenital Hearts (Global ARCH). Eur Heart J 2021;42:4213–4223.2Chessa M, Brida M, Gatzoulis MA, Diller GP, Roos-Hesselink JW, Dimopoulos K, Behringer W, Möckel M, Giamberti A, Galletti L, Price S, Baumgartner H, Gallego P, Tutarel O.

Emergency department management of patients with adult congenital heart disease. A consensus paper from the ESC Working Group on Adult Congenital Heart Disease, the European Society for Emergency Medicine (EUSEM), the European Association for Cardio-Thoracic Surgery (EACTS), and the Association for Acute Cardiovascular Care (ACVC). Eur Heart J 2021;42:2527–2535.3Diller GP, Gatzoulis MA, Broberg CS, Aboulhosn J, Brida M, Schwerzmann M, Chessa M, Kovacs AH, Roos-Hesselink J. antibiotics disease 2019 in adults with congenital heart disease. A position paper from the ESC working group of adult congenital heart disease, and the International Society for Adult Congenital Heart Disease.

Eur Heart J 2021;42:1858–1865.4Diller GP, Lammers AE, Enders D, Baumgartner H. Maternal and neonatal complications in women with congenital heart disease. Results from a nationwide analysis including 7,231 pregnancies. Eur Heart J 2020;41(Suppl_2). Doi:10.1093/eurheartj/ehaa946.2215.5Playan Escribano J, Segura De La Cal T, Segovia Cubero J, Rueda Soriano J, Garcia Hernandez FJ, Lopez Meseguer M, Perez Penate GM, Lara Padron A, Campo Ezquibela A, Sala Llinas E, Mombiela T, Guerra Ramos FJ, Samper GJ, Blanco I, Escribano Subias P, REHAP Investigators.

Pulmonary hypertension and congenital heart disease. Medical treatment and risk factors for survival. Eur Heart J 2020;41(Suppl_2). Doi:10.1093/eurheartj/ehaa946.2299.6Egidy Assenza G, Dimopoulos K, Budts W, Donti A, Economy KE, Gargiulo GD, Gatzoulis M, Landzberg MJ, Valente AM, Roos-Hesselink J. Management of acute cardiovascular complications in pregnancy.

Eur Heart J 2021;42:4224–4240.7Maas A, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, Kunadian V, Laan E, Lambrinoudaki I, Maclaran K, Panay N, Stevenson JC, van Trotsenburg M, Collins P. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions. A consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J 2021;42:967–984.8Al-Hussaini A. Pregnancy and aortic dissections.

Eur Heart J 2020;41:4243–4244.9Beyer SE, Dicks AB, Shainker SA, Feinberg L, Schermerhorn ML, Secemsky EA, Carroll BJ. Pregnancy-associated arterial dissections. A nationwide cohort study. Eur Heart J 2020;41:4234–4242.10Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, Jondeau G, Budts W, Grewal J, Sliwa K, Parsonage W, Maggioni AP, van Hagen I, Vahanian A, Tavazzi L, Elkayam U, Boersma E, Hall R. Pregnancy outcomes in women with cardiovascular disease.

Evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J 2019;40:3848–3855.11Koenig T, Hilfiker-Kleiner D. Future cardiovascular risk prediction in women with pregnancy complications. The HUNT is on. Eur Heart J 2019;40:1121–1123.12Diller GP, Orwat S, Lammers AE, Radke RM, De-Torres-Alba F, Schmidt R, Marschall U, Bauer UM, Enders D, Bronstein L, Kaleschke G, Baumgartner H.

Lack of specialist care is associated with increased morbidity and mortality in adult congenital heart disease. A population-based study. Eur Heart J 2021;42:4241–4248.13Khan AD, Valente AM. Don’t be alarmed. The need for enhanced partnerships between medical communities to improve outcomes for adults living with congenital heart disease.

Eur Heart J 2021;42:4249–4251.14Lammers AE, Diller G-P, Lober R, Möllers M, Schmidt R, Radke RM, De-Torres-Alba F, Kaleschke G, Marschall U, Bauer UM, Gerß J, Enders D, Baumgartner H. Maternal and neonatal complications in women with congenital heart disease. A nationwide analysis. Eur Heart J 2021;42:4252–4260.15Ramlakhan KP, Roos-Hesselink JW. Promising perspectives on pregnancy in women with congenital heart disease.

Eur Heart J 2021;42:4261–4263.16Ross SB, Jones K, Blanch B, Puranik R, McGeechan K, Barratt A, Semsarian C. A systematic review and meta-analysis of the prevalence of left ventricular non-compaction in adults. Eur Heart J 2020;41:1428–1436.17Rhee S, Paik DT, Yang JY, Nagelberg D, Williams I, Tian L, Roth R, Chandy M, Ban J, Belbachir N, Kim S, Zhang H, Phansalkar R, Wong KM, King DA, Valdez C, Winn VD, Morrison AJ, Wu JC, Red-Horse K. Endocardial/endothelial angiocrines regulate cardiomyocyte development and maturation and induce features of ventricular non-compaction. Eur Heart J 2021;42:4264–4276.18Wagner JUG, Dimmeler S.

The endothelial niche in heart failure. From development to regeneration. Eur Heart J 2021;42:4277–4279.19Wartolowska KA, Webb AJS. Big cohort studies offer insights into preventable risk factors. Eur Heart J 2021;42:4280–4281.20Huang HK, Liu PP, Hsu JY, Lin SM, Peng CC, Wang JH, Loh CH.

Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants. A real-world nationwide cohort study. Eur Heart J 2020;41:1100–1108.21Messerli FH, Bavishi C, Messerli AW, Siontis GCM. Cerebrotoxicity of antihypertensive therapy in the UK Biobank Cohort Study. Eur Heart J 2021;42:4282.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email. Journals.permissions@oup.com.This editorial refers to ‘Maternal and neonatal complications in women with congenital heart disease.

A nationwide analysis’, by A.E. Lammers et al., https://doi.org/10.1093/eurheartj/ehab571.With the increasing survival of children born with congenital heart disease into adult age, the focus has shifted from survival to quality of life. Most patients wish to live a normal life, including participation in sports and also starting a family. In earlier times, concerns were raised about the risks of pregnancy, as pregnancy is associated with impressive hormonal changes and haemodynamic impact. Older studies reported high rates of maternal complications, including maternal mortality, and substantial rates of perinatal complications.1–3 In addition, there were concerns about the hereditable recurrence risk of congenital heart disease for the baby.

However, studies were limited by small sample size or retrospective study design, and for a long time only the reported data from Nora and Nora were available.4 As a result, many physicians and, thus patients, were reluctant to embark on pregnancy, especially in more complex congenital heart disease, such as women with a systemic right ventricle, but also in severe aortic stenosis. The risks were deemed very high or too high, and these women were typically advised against pregnancy. Although research in the field of pregnancy and congenital heart disease is hampered by small numbers, often with retrospective design, over the past decades gradually some larger studies and registries became available, elucidating the risks of pregnancy and in fact showing relatively good results. A clear development over time in adult patients with congenital heart disease (ACHD) was seen for instance in women with transposition of the great arteries corrected with the Mustard and Senning operation, which started as being seen as very high risk, to high risk, and now to moderate risk. The trend for women with aortic stenosis is now also to allow pregnancy, even when the stenosis is severe, as long as the woman is asymptomatic.5–7The study of Lammers et al.

In this issue of the European Heart Journal provides an important contribution to the existing literature.8 Not only is this the largest study, but it includes all women with ACHD, without a possible bias of only including patients seen at a tertiary centre or including patients with other kinds of heart disease. Furthermore, because it is performed in a western country with an optimal healthcare system, the results are applicable to other western countries with comparable systems of care organization with appropriate counselling in place and good collaboration between cardiac and obstetric care. The pregnancy outcomes in studies with a global perspective, including patients from developing countries, show less favourable results (Graphical Abstract).8,9 These differences illustrate how the healthcare system and environment of women have great impact on their pregnancy outcomes and show that we still need to work to improve these outcomes for all women worldwide.10 A possible step forward is to utilize the expertise in the specialized healthcare centres such as described by Lammers et al., by providing long-distance digital or telephone consultations to rural centres in developing countries. Lammers et al. Also describe better pregnancy outcomes than an older study (1980–2007) in a Dutch and Belgian healthcare system similar to the German system, which may be due to advances in medical care for both the treatment of the original heart defect in the mother, and the management of pregnancy in heart disease, which includes the introduction of multidisciplinary pregnancy heart teams and the establishment of international guidelines (Graphical Abstract).8,11 Graphical AbstractComparison of studies on pregnancy outcomes of women with congenital heart disease.

ACHD. Adult congenital heart disease.Graphical AbstractComparison of studies on pregnancy outcomes of women with congenital heart disease. ACHD. Adult congenital heart disease.The most important finding of this well-performed and excellently written study is the zero maternal mortality in women with congenital heart disease.8 This is unexpected and fantastic news. As the authors point out, this is partly the result of good counselling, where the high-risk patients were advised against pregnancy and most probably did not become pregnant.

However, other studies show that some women at highest risk (mWHO IV) will actually still become pregnant, irrespective of counselling. In any case, this important finding makes it possible to reassure the large majority of ACHD patients about the mortality risk of pregnancy. This is an important message and should lead to a change in policy from approaching pregnancy as potentially very dangerous, to considering pregnancy as relatively safe and explaining the possible risks, on the condition that women in mWHO IV should not become pregnant. Of course morbidity is increased, but the rates are relatively low. The prevalence of heart failure in pregnancy might be under-reported in the study of Lammers et al., because pregnancies in women who had heart failure in the year before the pregnancy were not considered to be complicated by heart failure, probably because of the limitations of the method of registration with ICD codes.

The relationship between the occurrence of stroke and having a co-existent atrial septal defect or patent foramen ovale is shown nicely and should lead to a more proactive approach in taking lifestyle measures and considering a low threshold to prescribing antiplatelet drugs in these women. As in other studies, the mode of delivery is more often by Caesarean section in women with congenital heart disease, while this is not advised in the latest guidelines.6 An attempt must be made to change this policy, because planned Caesarean section in women with heart disease does not improve maternal outcome over vaginal delivery and can be harmful for neonatal outcome.12Another important finding of this study is the relatively high risk of the baby also having congenital heart disease.8 This study provides data on the numbers of children needing cardiac surgery with the use of cardiopulmonary bypass at young age, as a nice surrogate marker for congenital heart disease needing treatment, and reports 6% in ACHD patients vs. 0.4% in the general population. Scarce data were available on this topic, and for many years we had to rely on old studies.4 In particular, the comparison with the age-matched control group in this study provides the opportunity to finally gain reliable estimates. In counselling we can now inform our patients that the risk for their baby to also have congenital heart disease requiring surgery within ≤6 years is ∼15 times higher, compared with the general population (6% vs.

0.4%).8 What is astonishing is the reported rate for a univentricular heart being as high as 26.5%. Until now there was no reliable information on this specific congenital defect, because most women did not have children. However, this high rate fuels the discussion on pregnancy for women after Fontan correction. In addition to the high rates of miscarriage and maternal and foetal complications and the fear of the long-term impact on the maternal condition, now the high rate of foetal congenital defects also has to be taken into account when deciding on pregnancy in these high-risk women. It would be of interest to study trends over time, as earlier and better prenatal diagnostics and changes in termination management might have an impact, not only in these complex defects but also in less complex cardiac defects.In conclusion, the study by Lammers et al.

Is an excellent and clinically relevant contribution to the existing literature on pregnancy in women with congenital heart disease. The study shows that a good healthcare system, a multidisciplinary approach, and decisive pre-pregnancy counselling are effective in achieving safe pregnancies. Pre-pregnancy counselling with an individualized approach is a crucial step in this process, because both maternal and perinatal outcomes vary greatly by the complexity of maternal illness, and further studies dedicated to specific congenital diagnoses remain warranted.Conflict of interest. None declared.The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. References1Mendelson CL.

Pregnancy and coarctation of the aorta. Am J Obstet Gynecol 1940;39:1014–1021.2Arias F, Pineda J. Aortic stenosis and pregnancy. J Reprod Med 1978;20:229–232.3Presbitero P, Somerville J, Stone S, Aruta E, Spiegelhalter D, Rabajoli F. Pregnancy in cyanotic congenital heart disease.

Outcome of mother and fetus. Circulation 1994;89:2673–2676.4Nora JJ, Nora AH. Recurrence risks in children having one parent with a congenital heart disease. Circulation 1976;53:701–702.5Orwat S, Diller GP, van Hagen IM, Schmidt R, Tobler D, Greutmann M, Jonkaitiene R, Elnagar A, Johnson MR, Hall R, Roos-Hesselink JW, Baumgartner H. ROPAC Investigators.

Risk of pregnancy in moderate and severe aortic stenosis. From the multinational ROPAC registry. J Am Coll Cardiol 2016;68:1727–1737.6Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T, Swan L, Warnes CA. ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.

Eur Heart J 2018;39:3165–241.7Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, Jondeau G, Budts W, Grewal J, Sliwa K, Parsonage W, Maggioni AP, van Hagen I, Vahanian A, Tavazzi L, Elkayam U, Boersma E, Hall R. Pregnancy outcomes in women with cardiovascular disease. Evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J 2019;40:1–8.8Lammers AE, Diller GP, Lober R, Möllers M, Schmidt R, Radke RM, De-Torres-Alba F, Kaleschke G, Marschall U, Bauer UM, Gerβ J, Enders D, Baumgartner H. Maternal and neonatal complications in women with congenital heart disease.

A nationwide analysis. Eur Heart J 2021;42:4252–4260.9Ramlakhan KP, Johnson MR, Lelonek M, Saadd A, Gasimove Z, Sharashkinaf NV, Thorntong P, Arstallh M, Halli R, Roos-Hesselinka JW, on behalf of the ROPAC Investigators Group, ROPAC Executive Committee, ROPAC Investigators. Congenital heart disease in the ESC EORP Registry of Pregnancy and Cardiac disease (ROPAC). Int J Cardiol Congenital Heart Dis 2021;3:100107.10Independent Group of Scientists appointed by the Secretary-General. Global Sustainable Development Report 2019.

The Future is Now. Science for Achieving Sustainable Development. New York. 2019.11Drenthen W, Boersma E, Balci A, Moons P, Roos-Hesselink JW, Mulder BJ, Vliegen HW, van Dijk AP, Voors AA, Yap SC, van Veldhuisen DJ, Pieper PG. ZAHARA Investigators.

Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010;31:2124–2132.12Ruys TP, Roos-Hesselink JW, Pijuan-Domenech A, Vasario E, Gaisin IR, Iung B, Freeman LJ, Gordon EP, Pieper PG, Hall R, Boersma E, Johnson MR. ROPAC investigators. Is a planned caesarean section in women with cardiac disease beneficial?. Heart 2015;101:530–536.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email. Journals.permissions@oup.com..